Author: "Service de cardiologie [CHU de Poitiers]" - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Service de cardiologie [CHU de Poitiers]"' showing total 50 results

Start Over Author "Service de cardiologie [CHU de Poitiers]"

50 results on '"Service de cardiologie [CHU de Poitiers]"'

1. Optimisation of treatments for heart failure with reduced ejection fraction in routine practice: a position statement from a panel of experts

Author: Girerd, Nicolas, Leclercq, Christophe, Hanon, Olivier, Bayés-Genís, Antoni, Januzzi, James, Damy, Thibaut, Lequeux, Benoit, Meune, Christophe, Sabouret, Pierre, Roubille, François, Défaillance Cardiovasculaire Aiguë et Chronique (DCAC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Centre d'investigation clinique plurithématique Pierre Drouin [Nancy] (CIC-P), Centre d'investigation clinique [Nancy] (CIC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Cardiovascular and Renal Clinical Trialists [Vandoeuvre-les-Nancy] (INI-CRCT), Institut Lorrain du Coeur et des Vaisseaux Louis Mathieu [Nancy], French-Clinical Research Infrastructure Network - F-CRIN [Paris] (Cardiovascular & Renal Clinical Trialists - CRCT ), Laboratoire Traitement du Signal et de l'Image (LTSI), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pontchaillou [Rennes], Hôpitaux Universitaires Paris Centre, Université Paris Cité (UPCité), Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Germans Trias i Pujol University Hospital [Badalona, Barcelona, Spain] (GTPUH), Massachusetts General Hospital [Boston], Harvard Medical School [Boston] (HMS), Baim Institute for Clinical Research Boston MA, CHU Henri Mondor [Créteil], Service de cardiologie [CHU de Poitiers], Centre hospitalier universitaire de Poitiers (CHU Poitiers), Hôpital Avicenne [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut de cardiologie [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM)
Subjects: Titration, Cardiovascular diseases, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Practice guidelines treatment algorithm, Heart failure, Treatment optimization, [SDV.IB]Life Sciences [q-bio]/Bioengineering, General Medicine
Abstract: International audience; Major international practice guidelines recommend the use of a combination of 4 medication classes in the treatment of patients with heart failure with reduced ejection fraction (HFrEF) but do not specify how these treatments should be introduced and up-titrated. Consequently, many patients with HFrEF do not receive an optimized treatment regimen. This review proposes a pragmatic algorithm for treatment optimization designed to be easily applied in routine practice. The first goal is to ensure that all 4 recommended medication classes are initiated as early as possible to establish effective therapy, even at a low dose. This is considered preferable to starting fewer medications at a maximum dose. The second goal is to ensure that the intervals between the introduction of different medications and between different titration steps are as short as possible to ensure patient safety. Specific proposals are made for older patients (> 75 years) who are frail, and for those with cardiac rhythm disorders. Application of this algorithm should allow an optimal treatment protocol to be achieved within 2-months in most patients, which should the treatment goal in HFrEF.
Published: 2023
Full Text: View/download PDF

2. Follow-up of patients after revascularisation for peripheral arterial diseases: a consensus document from the European Society of Cardiology Working Group on Aorta and Peripheral Vascular Diseases and the European Society for Vascular Surgery

Author: Maarit Venermo, Tina Cohnert, Lucia Mazzolai, Ileana Desormais, Muriel Sprynger, Ross Naylor, Marco De Carlo, Victor Aboyans, Marianne Brodmann, Serge Kownator, Martin Björck, Jean-Baptiste Ricco, Christine Espinola-Klein, Charalambos Vlachopoulos, GIGA Cardiovascular Sciences [Liège, Belgium] (Department of Cardiology), University Hospital Sart Tilman [Liège, Belgium]-Heart Valve Clinic [Liège, Belgium], Service de Chirurgie Thoracique et Vasculaire - Médecine vasculaire [CHU Limoges], CHU Limoges, Neuroépidémiologie Tropicale (NET), Institut Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST), Université de Limoges (UNILIM)-Université de Limoges (UNILIM)-CHU Limoges-Institut d'Epidémiologie Neurologique et de Neurologie Tropicale-Institut National de la Santé et de la Recherche Médicale (INSERM), Uppsala Universitet [Uppsala], Centre Hospitalier Universitaire Vaudois [Lausanne] (CHUV), Service de cardiologie [CHU de Poitiers], Centre hospitalier universitaire de Poitiers (CHU Poitiers), Service de cardiologie [CHU Limoges], Verisuonikirurgian yksikkö, HUS Abdominal Center, and University of Helsinki
Subjects: Epidemiology, medicine.medical_treatment, Disease, Fibromuscular dysplasia, 030204 cardiovascular system & hematology, 0302 clinical medicine, follow-up, 030212 general & internal medicine, Societies, Medical, medicine.diagnostic_test, 3. Good health, Europe, Natural history, Treatment Outcome, IN-STENT RESTENOSIS, Cardiology, 030211 gastroenterology & hepatology, Cardiology and Cardiovascular Medicine, Vascular Surgical Procedures, medicine.medical_specialty, Consensus, Revascularisation, FIBROMUSCULAR DYSPLASIA, INFRAINGUINAL VEIN BYPASS, Physical examination, Revascularization, STENOSIS, restenosis, 03 medical and health sciences, peripheral arterial disease, Internal medicine, medicine, Humans, VELOCITY CRITERIA, business.industry, NATURAL-HISTORY, Perioperative, Vascular surgery, 3126 Surgery, anesthesiology, intensive care, radiology, medicine.disease, Stenosis, DUPLEX ULTRASOUND SURVEILLANCE, ENDOVASCULAR TREATMENT, 3121 General medicine, internal medicine and other clinical medicine, RISK-FACTORS, Surgery, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, CAROTID-ARTERY, business, 030217 neurology & neurosurgery, Follow-Up Studies
Abstract: International audience; Peripheral arterial diseases comprise different clinical presentations, from cerebrovascular disease down to lower extremity artery disease, from subclinical to disabling symptoms and events. According to clinical presentation, the patient's general condition, anatomical location and extension of lesions, revascularisation may be needed in addition to best medical treatment. The 2017 European Society of Cardiology guidelines in collaboration with the European Society for Vascular Surgery have addressed the indications for revascularisation. While most cases are amenable to either endovascular or surgical revascularisation, maintaining long-term patency is often challenging. Early and late procedural complications, but also local and remote recurrences frequently lead to revascularisation failure. The rationale for surveillance is to propose the accurate implementation of preventive strategies to avoid other cardiovascular events and disease progression and avoid recurrence of symptoms and the need for redo revascularisation. Combined with vascular history and physical examination, duplex ultrasound scanning is the pivotal imaging technique for identifying revascularisation failures. Other non-invasive examinations (ankle and toe brachial index, computed tomography scan, magnetic resonance imaging) at regular intervals can optimise surveillance in specific settings. Currently, optimal revascularisation surveillance programmes are not well defined and systematic reviews addressing long-term results after revascularisation are lacking. We have systematically reviewed the literature addressing follow-up after revascularisation and we propose this consensus document as a complement to the recent guidelines for optimal surveillance of revascularised patients beyond the perioperative period.
Published: 2019
Full Text: View/download PDF

3. Phenotype/Genotype Relationship in Left Ventricular Noncompaction: Ion Channel Gene Mutations Are Associated With Preserved Left Ventricular Systolic Function and Biventricular Noncompaction

Author: Marie Cambon-Viala, Erwan Donal, Jean-Christophe Eicher, Guillaume Jondeau, Philippe Charron, Caroline Sawka, Christine Selton-Suty, Jean-François Pruny, Pascale Richard, Valeria Donghi, Anne-Claire Casalta, Hilla Gerard, Olivier Huttin, Karine Nguyen, Flavie Ader, Hélène Martel, Nicolas Michel, Laurence Faivre, Pascale Raud-Raynier, Nicolas Mansencal, Gilbert Habib, Département de Cardiologie [Hôpital de la Timone - APHM], Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Département de génétique médicale [Hôpital de la Timone - APHM], Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE)-Institut National de la Santé et de la Recherche Médicale (INSERM), Sorbonne Université (SU), Institut de Mécanique Céleste et de Calcul des Ephémérides (IMCCE), Institut national des sciences de l'Univers (INSU - CNRS)-Observatoire de Paris, Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université de Lille-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Microbes évolution phylogénie et infections (MEPHI), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Hôpital de la Timone [CHU - APHM] (TIMONE)-Assistance Publique - Hôpitaux de Marseille (APHM), Hôpital de la Timone [CHU - APHM] (TIMONE), Marseille medical genetics - Centre de génétique médicale de Marseille (MMG), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] (IHU ICAN), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] (IHU ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre de Référence Maladies Cardiaques Héréditaires, CHU Pontchaillou [Rennes], CHU Dijon, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Service de Cardiologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Service de cardiologie [CHU de Poitiers], Centre hospitalier universitaire de Poitiers (CHU Poitiers), AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Laboratoire de Recherche Vasculaire Translationnelle (LVTS (UMR_S_1148 / U1148)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord, Hôpital Ambroise Paré [AP-HP], FHU TRANSLAD (CHU de Dijon), Université de Bourgogne (UB), and Institut Hospitalier Universitaire Méditerranée Infection (IHU Marseille)
Subjects: Bradycardia, medicine.medical_specialty, Left ventricular noncompaction, phenotype, genotype, Genetic counseling, registry, 030204 cardiovascular system & hematology, Gene mutation, medicine.disease_cause, 03 medical and health sciences, 0302 clinical medicine, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Internal medicine, Genotype, medicine, echocardiography, [SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology, 030212 general & internal medicine, ComputingMilieux_MISCELLANEOUS, Mutation, [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases, Ejection fraction, business.industry, Phenotype, [SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology, 3. Good health, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, Cardiology, medicine.symptom, Cardiology and Cardiovascular Medicine, business
Abstract: International audience; Background: Few data exist concerning genotype-phenotype relationships in left ventricular noncompaction (LVNC).Methods and results: From a multicenter French Registry, we report the genetic and clinical spectrum of 95 patients with LVNC, and their genotype-phenotype relationship. Among the 95 LVNC, 45 had at least 1 mutation, including 14 cases of mutation in ion channel genes. In a complementary analysis including 16 additional patients with ion channel gene mutations, for a total of 30 patients with ion channel gene mutation, we found that those patients had higher median LV ejection fraction (60% vs 40%; P < .001) and more biventricular noncompaction (53.1% vs 18.5%; P < .001) than the 81 other patients with LVNC. Among them, both the 19 patients with an HCN4 mutation and the 11 patients with an RYR2 mutation presented with a higher LV ejection fraction and more frequent biventricular noncompaction than the 81 patients with LVNC but with no mutation in the ion channel gene, but only patients with HCN4 mutation presented with a lower heart rate.Conclusions: Ion channel gene mutations should be searched systematically in patients with LVNC associated with either bradycardia or biventricular noncompaction, particularly when LV systolic function is preserved. Identifying causative mutations is of utmost importance for genetic counselling of at-risk relatives of patients affected by LVNC.
Published: 2021
Full Text: View/download PDF

4. Position paper on stress cardiac magnetic resonance imaging in chronic coronary syndrome: Endorsed by the Société française de radiologie (SFR), the Société française d’imagerie cardiovasculaire (SFICV) and the Société française de cardiologie (SFC)

Author: Laurent Macron, Martine Gilard, Jean-Nicolas Dacher, Florent Le Ven, François Pontana, Gilles Barone-Rochette, Damien Mandry, Louis Boyer, Alain Furber, Alexis Jacquier, Olivier Genée, Jérôme Garot, Luc-Philippe Christiaens, Groupe d'Etude de la Thrombose de Bretagne Occidentale (GETBO), Université de Brest (UBO)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO)-Université de Brest (UBO), Endothélium, valvulopathies et insuffisance cardiaque (EnVI), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Récepteurs Nucléaires, Maladies Métaboliques et Cardiovasculaires (RNMCD - U1011), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Pole Cardio-vasculaire et pulmonaire [CHU Lille], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre Hospitalier Universitaire [Grenoble] (CHU), Radiopharmaceutiques biocliniques (LRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Grenoble Alpes (UGA), French-Clinical Research Infrastructure Network - F-CRIN [Paris] (Cardiovascular & Renal Clinical Trialists - CRCT ), Centre cardiologique du Nord (CCN), Hôpital Privé Jacques Cartier [Massy], Pôle santé Oréliance, Imagerie Adaptative Diagnostique et Interventionnelle (IADI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Département de Radiologie adultes [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Université de Lorraine (UL), Service de cardiologie [CHU de Poitiers], Centre hospitalier universitaire de Poitiers (CHU Poitiers), Optimisation des régulations physiologiques (ORPHY (EA 4324)), Université de Brest (UBO)-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)-Institut Brestois Santé Agro Matière (IBSAM), CHU Gabriel Montpied [Clermont-Ferrand], CHU Clermont-Ferrand, Physiopathologie Cardiovasculaire et Mitochondriale (MITOVASC), Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre de résonance magnétique biologique et médicale (CRMBM), Assistance Publique - Hôpitaux de Marseille (APHM)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Brestois Santé Agro Matière (IBSAM), Récepteurs Nucléaires, Maladies Métaboliques et Cardiovasculaires - U1011 (RNMCD), MitoVasc - Physiopathologie Cardiovasculaire et Mitochondriale (MITOVASC), Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Centre National de la Recherche Scientifique (CNRS), and DACHER, Jean Nicolas
Subjects: Adult, Male, Techniques d’imagerie cardiaque, Myocardial ischaemia, Angor, Consensus, Delphi Technique, Vasodilator Agents, Angina pectoris, Myocardial Ischemia, Cardiac imaging techniques, 030204 cardiovascular system & hematology, Coronaropathie stable, 03 medical and health sciences, 0302 clinical medicine, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Predictive Value of Tests, Coronary Circulation, Medicine, Humans, 030212 general & internal medicine, Stress Cardiac Magnetic Resonance Imaging, Aged, medicine.diagnostic_test, business.industry, Hemodynamics, Magnetic resonance imaging, General Medicine, Adrenergic beta-Agonists, Middle Aged, Prognosis, Magnetic Resonance Imaging, 3. Good health, Acquisition Protocol, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Risk stratification, Chronic Disease, Ischémie myocardique, Position paper, Cardiac Imaging Techniques, Female, Stable coronary artery disease, Cardiology and Cardiovascular Medicine, business, Nuclear medicine
Abstract: International audience; This paper is intended to update the former consensus between the French Societies of Radiology and Cardiology about the use of stress cardiac magnetic resonance imaging in chronic coronary syndrome, published in 2009. The Delphi method was used to build the present consensus. This expert panel consensus includes recommendations for indications, the procedure (with patient preparation), stress-inducing drugs, the acquisition protocol, interpretation and risk stratification by stress magnetic resonance imaging.
Published: 2021
Full Text: View/download PDF

5. Position paper on stress cardiac MRI in chronic coronary syndrome: Endorsed by the Société Française de Radiologie (SFR) the Société Française d’Imagerie CardioVasculaire (SFICV) and the Société Française de Cardiologie (SFC)

Author: Florent Le Ven, Luc Christiaens, Alexis Jacquier, Martine Gilard, Jérôme Garot, Olivier Genée, François Pontana, Louis Boyer, Alain Furber, Laurent Macron, Damien Mandry, Jean-Nicolas Dacher, Gilles Barone-Rochette, Groupe d'Etude de la Thrombose de Bretagne Occidentale (GETBO), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO)-Université de Brest (UBO), Récepteurs Nucléaires, Maladies Métaboliques et Cardiovasculaires - U1011 (RNMCD), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Radiopharmaceutiques biocliniques (LRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Grenoble Alpes (UGA), Centre cardiologique du Nord (CCN), Hôpital Privé Jacques Cartier [Massy], Pôle santé Oréliance, Imagerie Adaptative Diagnostique et Interventionnelle (IADI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Département de Radiologie adultes [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Université de Lorraine (UL), Service de cardiologie [CHU de Poitiers], Centre hospitalier universitaire de Poitiers (CHU Poitiers), MitoVasc - Physiopathologie Cardiovasculaire et Mitochondriale (MITOVASC), Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Endothélium, valvulopathies et insuffisance cardiaque (EnVI), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de résonance magnétique biologique et médicale (CRMBM), Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Centre National de la Recherche Scientifique (CNRS), Hôpital de la Cavale Blanche - CHRU Brest (CHU - BREST ), Institut Pascal (IP), Centre National de la Recherche Scientifique (CNRS)-Université Clermont Auvergne (UCA)-Institut national polytechnique Clermont Auvergne (INP Clermont Auvergne), Université Clermont Auvergne (UCA)-Université Clermont Auvergne (UCA), Université de Brest (UBO)-Institut Brestois Santé Agro Matière (IBSAM), Récepteurs Nucléaires, Maladies Métaboliques et Cardiovasculaires (RNMCD - U1011), Physiopathologie Cardiovasculaire et Mitochondriale (MITOVASC), Assistance Publique - Hôpitaux de Marseille (APHM)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), and DACHER, Jean Nicolas
Subjects: medicine.medical_specialty, Myocardial ischemia, Angina pectoris, 030218 nuclear medicine & medical imaging, 03 medical and health sciences, 0302 clinical medicine, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Internal medicine, Stress (linguistics), medicine, Radiology, Nuclear Medicine and imaging, Stable coronary artery disease, Cardiac MRI, Stress Cardiac Magnetic Resonance Imaging, Radiological and Ultrasound Technology, business.industry, General Medicine, 3. Good health, Acquisition Protocol, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, 030220 oncology & carcinogenesis, Risk stratification, Cardiology, Position paper, business
Abstract: International audience; This position paper was intended to update the former consensus between the French Societies of Radiology and Cardiology about the use of stress cardiac magnetic resonance imaging (MRI) in chronic coronary syndrome published in 2009. The Delphi method was used to build the present consensus. This expert panel consensus includes recommendations for indications, procedure with patient preparation, stress inducing drugs, acquisition protocol, interpretation and risk stratification by stress MRI.
Published: 2021
Full Text: View/download PDF

6. Effectiveness of Deep Sedation for Patients With Intractable Electrical Storm Refractory to Antiarrhythmic Drugs

Author: Nicolas Barbarot, Charles Guenancia, Christophe Leclercq, Audrey Sagnard, Arnaud Bisson, David Hamon, Laure Champ-Rigot, Paul Milliez, Estelle Gandjbakhch, Lionel Borella, D. Pavin, Bruno Degand, Nathalie Behar, Frederic Sacher, Nicolas Lellouche, Pierre Bouju, Rodrigue Garcia, Vincent Galand, Jean-Marc Sellal, Philippe Mabo, Raphaël P. Martins, Angélique Goepp, Josselin Duchateau, E. Varlet, Romain Tixier, Nicolas Clementy, Guillaume Rieul, Jean-Marie Urien, Christian de Chillou, Stéphane Schumacher, Eloi Marijon, Laboratoire Traitement du Signal et de l'Image (LTSI), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pontchaillou [Rennes], Hôpital de St Brieuc, Service de Cardiologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Service de cardiologie [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Service de Cardiologie [CHU de Dijon], Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Service de Cardiologie [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université, Service de Cardiologie [Bordeaux], CHU Bordeaux [Bordeaux], Centre hospitalier de Vannes, Service de Cardiologie [Henri Mondor], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor, Service de cardiologie et de pathologie vasculaire [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Hôpital Européen Georges Pompidou [APHP] (HEGP), Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de cardiologie [CHU de Poitiers], Centre hospitalier universitaire de Poitiers (CHU Poitiers), Centre hospitalier de Lorient, Imagerie Adaptative Diagnostique et Interventionnelle (IADI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU de Saint-Brieuc, CHU Trousseau [Tours], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CH Vannes, Hôpital Henri Mondor, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), CH de Lorient, Centre de recherche Cardio-Thoracique de Bordeaux [Bordeaux] (CRCTB), Université Bordeaux Segalen - Bordeaux 2-CHU Bordeaux [Bordeaux]-Institut National de la Santé et de la Recherche Médicale (INSERM), and Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)
Subjects: cardiac, [SDV]Life Sciences [q-bio], Sedation, Hospital mortality, 030204 cardiovascular system & hematology, 03 medical and health sciences, 0302 clinical medicine, Refractory, Physiology (medical), Medicine, Humans, 030212 general & internal medicine, ComputingMilieux_MISCELLANEOUS, Aged, hospital mortality, business.industry, Storm, 3. Good health, Anesthesia, Tachycardia, Ventricular, [SDV.IB]Life Sciences [q-bio]/Bioengineering, medicine.symptom, Deep Sedation, Cardiology and Cardiovascular Medicine, business, arrhythmias, Anti-Arrhythmia Agents
Abstract: International audience
Published: 2020
Full Text: View/download PDF

7. Blunting periprocedural myocardial necrosis: Rationale and design of the randomized ALPHEUS study

Author: François Jourda, Christophe Saint-Etienne, Luc Christiaens, Grégoire Rangé, Benoit Lattuca, Philippe Brunel, Paul Guedeney, Hervé Le Breton, Marie Hauguel-Moreau, Eric Vicaut, Anne Bellemain-Appaix, Jean-Louis Georges, Guillaume Cayla, Christophe Pouillot, Christophe Caussin, Gregory Ducrocq, Ziad Boueri, Farzin Beygui, Johanne Silvain, Thibault Lhermusier, Gilles Montalescot, Jean-Noël Labèque, Jean-Philippe Collet, Zuzana Motovska, Franck Boccara, Mohamad El Kasty, Raphaelle Dumaine, Jean-Guillaume Dillinger, Mikael Laredo, Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases [IHU ICAN], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] (IHU ICAN), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Universitaire Carémeau [Nîmes] (CHU Nîmes), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Service de cardiologie et de pathologie vasculaire [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Service de cardiologie [Chartres], Les hôpitaux de Chartres [Chartres], Marqueurs cardiovasculaires en situation de stress (MASCOT (UMR_S_942 / U942)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPC)-Université Sorbonne Paris Nord, Hôpital de Bastia, Service de Cardiologie [Hôpital privé Dijon Bourgogne], Hôpital privé Dijon Bourgogne, Clinique Sainte Clotilde, Centre de Recherche Saint-Antoine (CRSA), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Service de cardiologie [CHU de Poitiers], Centre hospitalier universitaire de Poitiers (CHU Poitiers), Service de cardiologie [Centre Hospitalier de la Côte Basque, Bayonne], Centre Hospitalier de la Côte Basque, CHU Toulouse [Toulouse], Centre Hospitalier de Versailles André Mignot (CHV), Cardiology Department, Centre Hospitalier d'Antibes Juan les Pins, Antibes, Laboratoire Traitement du Signal et de l'Image (LTSI), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pontchaillou [Rennes], Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Trousseau [APHP], Institut Mutualiste de Montsouris (IMM), Hôpital d'Auxerre, Partenaires INRAE, Grand Hôpital de l'Est Francilien (GHEF), Laboratoire de Recherche Vasculaire Translationnelle (LVTS (UMR_S_1148 / U1148)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPC)-Université Sorbonne Paris Nord, AstraZeneca France Novartis Daiichi-Sankyo Bristol-Myers Squibb, BMS Eli Lilly and Company Bayer AstraZeneca France Boston Scientific Corporation, BSC Abbott Laboratories Medtronic Biotronik Fédération Française de Cardiologie, FFC, The ALPHEUS and the Bio-ALPHEUS studies are funded by the Fond de dotation ACTION ( www.action-fonds.org ) and a grant from AstraZeneca . The Bio-ALPHEUS study is also funded by the Institute of Cardiometabolism and Nutrition . The first draft of the paper was developed by Dr Silvain and Dr Montalescot, and all authors subsequently contributed to its development and final content and are solely responsible for the design and conduct of this study, all study analyses, the drafting and editing of the paper, and its final contents. AstraZeneca reviewed the manuscript and was allowed to make suggestions, but final content was determined by the authors., Dr Silvain reports receiving consulting and lecture or travel support from AstraZeneca, Bayer HealthCare SAS, Biotronik, BPI France, Boehringer Ingelheim France, CSL Behring SA, Gilead Science, Sanofi-Aventis France, Terumo France SAS, Abbott Medical France SAS, and Zoll and is a stockholder of Pharmaseeds. Dr Cayla reports speaker or congress fees and has received research grants/consultant fees/lectures fees from Amgen, AstraZeneca, Abbott, Bayer, Biotronik, Bristol-Myers Squibb, Pfizer, and Sanofi-Aventis. Dr Beygui reports receiving consulting and lecture fees from Astrazeneca, Bristol-Myers Squibb, Medtronic, Biosensors, Boston Scientific Institutional and research grants from Medtronic, Biosensors, Acist, and Boston scientific. Dr Rangé reports receiving speaker’s and/or consulting fees from Abbott. Dr Lattuca has received research grants from Biotronik, Boston Scientific, Daiichi-Sankyo, Fédération Française de Cardiologie, and Institute of CardioMetabolism and Nutrition, consultant fees from Daiichi-Sankyo and Eli Lilly, and lecture fees from AstraZeneca, Medtronic, and Novartis. Dr Collet reports receiving consulting and lecture fees from AstraZeneca, Bayer, Bristol-Myers Squibb, Fédération Française de Cardiologie, Lead-Up, Medtronic, MSD, Sanofi-Aventis, and WebMD. Dr Dillinger reports receiving consulting and lecture fees from AstraZeneca, Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb/Pfizer, and Sanofi and grants from Bayer, Bristol-Myers Squibb/Pfizer, and Biosensors. Dr Boueri reports receiving consulting and lecture fees from Novartis and Astra Zeneca. Dr Boccara reports consulting or speaker fees from Amgen, Gilead, ViiV Healthcare, Amgen, Sanofi, MSD, and Servier outside the submitted work. Dr Christiaens reports consulting or speaker fees from Astra Zeneca. Dr Lhermusier reports consulting or speaker fees from Astra Zeneca, Boston Scientifics, and Abbott and a research grant from Astra Zeneca. Dr Georges reports consulting or speaker fees from AstraZeneca France, Sanofi-Aventis, Amgen, and Merck Sharpe and Dohme. Dr Bellemain-Appaix reports consulting or speaker fees from Astra Zeneca, Novartis, and Pfizer. Dr Saint-Etienne reports consulting or speaker fees from Abbott, Medtronic, Edwards, and Biotronik. Dr Motovska reports consulting or speaker fees from Astrazeneca. Dr Laredo reports fellowship grants from Medtronic, Biotronik, and Boston Scientific. Dr Ducrocq reports consulting or speaker fees from Amgen, Astra Zeneca, Bayer, BMS, Janssen, Sanofi, and Terumo, proctoring: Boston scientific, CEC: Novo Nordisk, and travel fees: Astra Zeneca, Bayer, and BMS. Dr Vicaut reports consulting or speaker fees from Abbott, Bristol Myers Squibb, Celgene, Edwards, Pfizer, Sanofi, and Novartis. Dr Montalescot reports consulting or speaker fees from Abbott, AIM group, Amgen, Actelion, American College of Cardiology Foundation, Astrazeneca, Axis-Santé, Bayer, Boston-Scientific, Bristol-Myers Squibb, Beth Israel Deaconess Medical, Brigham Women’s Hospital, Fréquence Médicale, ICOM, Idorsia, Elsevier, Fédération Française de Cardiologie, Fréquence Médicale, Institute of Cardiometabolism and Nutrition, Lead-Up, Menarini, Medtronic, MSD, Novo-Nordisk, Pfizer, Quantum Genomics, Sanofi-Aventis, SCOR global life, Servier, and WebMD. Other authors have no conflict of interest to report., Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Institute of cardiometabolism and nutrition (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS)-Université de Paris (UP)-Université Sorbonne Paris Nord, Centre de Recherche Saint-Antoine (CR Saint-Antoine), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP)-Université Sorbonne Paris Nord, Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord, Centre Hospitalier de la Côte Basque (CHCB), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre hospitalier d'Auxerre (CHA), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord
Subjects: medicine.medical_specialty, Ticlopidine, medicine.medical_treatment, Myocardial Infarction, Coronary Disease, 030204 cardiovascular system & hematology, Coronary Angiography, Loading dose, Coronary artery disease, 03 medical and health sciences, 0302 clinical medicine, Percutaneous Coronary Intervention, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Internal medicine, medicine, Humans, 030212 general & internal medicine, Myocardial infarction, cardiovascular diseases, Aged, Aspirin, business.industry, Percutaneous coronary intervention, medicine.disease, Clopidogrel, 3. Good health, Conventional PCI, Cardiology, Purinergic P2Y Receptor Antagonists, [SDV.IB]Life Sciences [q-bio]/Bioengineering, Cardiology and Cardiovascular Medicine, business, Ticagrelor, Platelet Aggregation Inhibitors, medicine.drug
Abstract: International audience; Background: Clopidogrel associated with aspirin is the recommended treatment for patients undergoing elective percutaneous coronary intervention (PCI). Although severe PCI-related events are rare, evidence suggests that PCI-related myocardial infarction and myocardial injury are frequent complications that can impact the clinical prognosis of the patients. Antiplatelet therapy with a potent P2Y12 receptor inhibitor such as ticagrelor may reduce periprocedural ischemic complications while maintaining a similar safety profile as compared with conventional dual antiplatelet therapy by aspirin and clopidogrel in this setting. Methods: Assessment of Loading with the P2Y12 inhibitor ticagrelor or clopidogrel to Halt ischemic Events in patients Undergoing elective coronary Stenting (ALPHEUS) (NCT02617290) is an international, multicenter, randomized, parallel-group, open-label study in patients with stable coronary artery disease who are planned for an elective PCI. In total, 1,900 patients will be randomized before a planned PCI to a loading dose of ticagrelor 180 mg or a loading dose of clopidogrel (300 or 600 mg) in addition to aspirin. Patients will then receive a dual antiplatelet therapy with aspirin and ticagrelor 90 mg twice daily or clopidogrel 75 mg once daily for 30 days. The primary ischemic end point is PCI-related myocardial infarction (myocardial infarction type 4a or 4b) or major myocardial injury within 48 hours (or at hospital discharge if earlier) after elective PCI/stent. Safety will be evaluated by major bleeding events (Bleeding Academic Research Consortium type 3 or 5) at 48 hours (or discharge if it occurs earlier). Conclusion: ALPHEUS is the first properly sized trial comparing ticagrelor to clopidogrel in the setting of elective PCI and is especially designed to show a reduction in periprocedural events, a surrogate end point for mortality.
Published: 2020
Full Text: View/download PDF

8. Management of Patients with Asymptomatic and Symptomatic Carotid Artery Disease: Update on Anti-Thrombotic Therapy

Author: Victor Aboyans, Francesco Violi, Jean-Baptiste Ricco, Manesh R. Patel, Jackie Bosch, Eike Sebastian Debus, Peter Verhamme, Jean-François Tanguay, Rupert Bauersachs, Daniele Pastori, Lucia Mazzolai, Sonia S. Anand, John W. Eikelboom, Mark R. Nehler, Sigrid Nikol, McMaster University [Hamilton, Ontario], Divisions of Cardiology and Thromboembolism McMaster University Hamiton, Service de cardiologie [CHU de Poitiers], Centre hospitalier universitaire de Poitiers (CHU Poitiers), Klinikum Darmstadt (RMB), Klinikum Darmstadt, Population Health Research Institute, Service de Chirurgie Thoracique et Vasculaire - Médecine vasculaire [CHU Limoges], CHU Limoges, Neuroépidémiologie Tropicale (NET), CHU Limoges-Institut d'Epidémiologie Neurologique et de Neurologie Tropicale-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST), Université de Limoges (UNILIM)-Université de Limoges (UNILIM), Grelier, Elisabeth, Institut Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST), and Université de Limoges (UNILIM)-Université de Limoges (UNILIM)-CHU Limoges-Institut d'Epidémiologie Neurologique et de Neurologie Tropicale-Institut National de la Santé et de la Recherche Médicale (INSERM)
Subjects: Carotid Artery Diseases, Male, Risk, 0301 basic medicine, medicine.medical_specialty, Cardiology, Hemorrhage, Thromboembolic stroke, 030204 cardiovascular system & hematology, Asymptomatic, 03 medical and health sciences, 0302 clinical medicine, Rivaroxaban, Carotid artery disease, Internal medicine, Ischaemic stroke, Myocardial Revascularization, medicine, Humans, Aged, Aspirin, business.industry, Incidence (epidemiology), Atherosclerotic disease, Anticoagulants, Atrial fibrillation, Hematology, Middle Aged, Atherosclerosis, medicine.disease, Clopidogrel, Review article, Carotid Arteries, 030104 developmental biology, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, Cardiovascular Diseases, anti-platelet, anti-thrombotic therapy, anticoagulant, aspirin, carotid artery disease, rivaroxaban, Female, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, medicine.symptom, business, Platelet Aggregation Inhibitors
Abstract: The most common causes of ischaemic stroke are represented by carotid artery atherosclerotic disease (CAAD) and atrial fibrillation. While oral anticoagulants substantially reduce the incidence of thromboembolic stroke (< 1%/year), the rate of ischaemic stroke and other cardiovascular disease events in patients with CAAD remains high, ranging from 8.4 to 18.1 events per 100 patient-years. Similar to any other atherosclerotic disease, anti-thrombotic therapies are proposed for CAAD to reduce stroke and other cardiovascular events. The 2017 European Society of Cardiology (ESC)/European Society for Vascular Surgery (ESVS) guidelines recommend for patients with asymptomatic CAAD ≥60% the use of aspirin 75 to 100 mg once daily or clopidogrel 75 mg once daily at the exception of patient at very high bleeding risk. For patients with symptomatic CAAD ≥50%, the use of aspirin 75 to 100 mg once daily or clopidogrel 75 mg once daily is recommended. New perspectives for anti-thrombotic therapy for the treatment of patients with CAAD come from the novel dual pathway strategy combining a low-dose anticoagulant (i.e. rivaroxaban) and aspirin that may help reduce long-term ischaemic complications in patients with CAAD. This review summarizes current evidence and recommendations for the anti-thrombotic management of patients with symptomatic or asymptomatic CAAD or those undergoing carotid revascularization.
Published: 2019
Full Text: View/download PDF

9. Normative and pathological values of hemodynamic and Doppler ultrasound arterial findings in children

Author: Jean-Eudes Trihan, Antonia Perez-Martin, Jérôme Guillaumat, Damien Lanéelle, Service de cardiologie [CHU de Poitiers], Centre hospitalier universitaire de Poitiers (CHU Poitiers), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Université de Caen Normandie - UFR Santé (UNICAEN Santé), Université de Caen Normandie (UNICAEN), and Normandie Université (NU)-Normandie Université (NU)
Subjects: medicine.medical_specialty, MESH: Hemodynamics, Velocities, Hemodynamics, 030204 cardiovascular system & hematology, 030218 nuclear medicine & medical imaging, 03 medical and health sciences, symbols.namesake, 0302 clinical medicine, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Internal medicine, medicine, Doppler measurements, [INFO.INFO-IM]Computer Science [cs]/Medical Imaging, Humans, Child, Pathological, Children, MESH: Arteries, Pediatric, MESH: Angiography, [SDV.MHEP.PED]Life Sciences [q-bio]/Human health and pathology/Pediatrics, business.industry, Pediatric imaging, Angiography, Ultrasonography, Doppler, Blood flow, MESH: Blood Flow Velocity, Arteries, 3. Good health, Cardiology, symbols, MESH: Ultrasonography, Doppler, Normative, Doppler ultrasound, Spectrum analysis, Cardiology and Cardiovascular Medicine, business, Doppler effect, Blood Flow Velocity
Abstract: International audience; Summary. Doppler ultrasound is an effective, useful and remarkably powerful tool in pediatric imaging. If possible, its use is always favored to avoid exposure to radiation or sedatives. By waveform spectrum analysis, Doppler ultrasound reveals information on blood flow and details on normal physiology and pathological processes undiscernible from gray-scale imaging alone. However, Doppler ultrasound remains underused, largely due to the difficult interpretation of changes in Doppler waveforms during childhood. This article provides a narrative review of the literature regarding the normative values and the physiological arterial changes through childhood according to age, weight or height, as well as frequent pathological arterial findings in children, classified by arterial territory.
Published: 2020
Full Text: View/download PDF

10. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS)

Author: Martin Czerny, Maarit Venermoa, Marianne Brodmann, Sebastian Debusa, Marie-Louise Bartelink, Gunnar Tepe, Victor Aboyans, Lucia Mazzolai, Thomas Kahan, A Ross Naylora, Michal Tendera, Muriel Sprynger, Marco Roffi, Jean-Baptiste Ricco, Martin Björck, Jean-Philippe Collet, Marco De Carlo, Christine Espinola-Klein, Charalambos Vlachopoulos, Joachim Rotherb, Tina Cohnert, Ileana Desormais, Serge Kownator, Service de Chirurgie Thoracique et Vasculaire - Médecine vasculaire [CHU Limoges], CHU Limoges, Neuroépidémiologie Tropicale (NET), Institut Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST), Université de Limoges (UNILIM)-Université de Limoges (UNILIM)-CHU Limoges-Institut d'Epidémiologie Neurologique et de Neurologie Tropicale-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de cardiologie [CHU de Poitiers], Centre hospitalier universitaire de Poitiers (CHU Poitiers), Department of Internal Medicine, Medizinische Universität Graz, Institut de cardiologie [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet [Stockholm], Centre Hospitalier Universitaire de Liège (CHU-Liège), Third Division of Cardiology, Medical University of Silesia (SUM), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), and Medical University of Silesia
Subjects: Male, medicine.medical_specialty, Cardiology, MEDLINE, 030204 cardiovascular system & hematology, Peripheral Arterial Disease, 03 medical and health sciences, 0302 clinical medicine, Internal Medicine, medicine, Humans, 030212 general & internal medicine, Intensive care medicine, ComputingMilieux_MISCELLANEOUS, Societies, Medical, reproductive and urinary physiology, urogenital system, business.industry, General Medicine, Vascular surgery, Peripheral Arterial Diseases, 3. Good health, Europe, embryonic structures, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Female, biological phenomena, cell phenomena, and immunity, Cardiology and Cardiovascular Medicine, business
Abstract: [2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS)]
Published: 2017
Full Text: View/download PDF

11. Subcutaneous cardioverter defibrillator has longer time to therapy but is less cardiotoxic than transvenous cardioverter defibrillator. Study carried out in a preclinical porcine model

Author: Rodrigue Garcia, Bruno Degand, Patrick Bruneval, Thomas Kerforne, Jamil Hajj-Chahine, Christophe Jayle, Frédéric Favreau, Sofiane Inal, Thierry Hauet, Centre hospitalier universitaire de Poitiers (CHU Poitiers), Ischémie Reperfusion en Transplantation d’Organes Mécanismes et Innovations Thérapeutiques ( IRTOMIT), Université de Poitiers-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service d'anatomo-pathologie [CHU HEGP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Service de cardiologie [CHU de Poitiers], and Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Poitiers
Subjects: medicine.medical_specialty, Swine, [SDV]Life Sciences [q-bio], medicine.medical_treatment, Electric Countershock, Defibrillation, 030204 cardiovascular system & hematology, 03 medical and health sciences, 0302 clinical medicine, Troponin T, Physiology (medical), Internal medicine, medicine, Animals, Ventricular fibrillation, 030212 general & internal medicine, Creatine Kinase, Cardiotoxicity, biology, business.industry, Cardiac arrhythmia, Shock, Equipment Design, medicine.disease, Implantable cardioverter-defibrillator, Defibrillators, Implantable, 3. Good health, Disease Models, Animal, Preclinical study, Treatment Outcome, Shock (circulatory), Toxicity, biology.protein, Cardiology, Transvenous implantable cardioverter, Creatine kinase, Medical emergency, medicine.symptom, Cardiology and Cardiovascular Medicine, business, Transvenous implantable cardioverter defibrillator, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract: International audience; Aims Totally subcutaneous implantable cardioverter defibrillator (S-ICD) delivers higher shock energy and can have longer time to therapy compared to transvenous implantable cardioverter defibrillator (T-ICD). Aim of the study was to compare time to therapy and to investigate cardiac, cerebral and systemic injuries of S-ICD and T-ICD shocks delivered after ventricular fibrillation (VF) induction. Methods and results Fourteen pigs were randomly implanted with a S-ICD (n = 7) or a T-ICD (n = 7). Five VF episodes were induced in each pig. For each VF episode, up to two shocks could be delivered by the T-ICD or the S-ICD to terminate the arrhythmia. Cardiac, systemic, and cerebral toxicity were monitored. Mean time to therapy was longer in the S-ICD group compared to the T-ICD group (19[18; 23] s vs. 9 [7; 10] s; P = 0.001, respectively). High-sensitivity troponin T levels were significantly higher in the T-ICD group from 1 to 24 h after the procedure (P
Published: 2017
Full Text: View/download PDF

12. Corrigendum to ‘Global Vascular Guidelines on the Management of Chronic Limb-Threatening Ischemia’ [European Journal of Vascular & Endovascular Surgery 58/1S (2019) 1–109]

Author: Conte, Michael, Bradbury, Andrew, Kolh, Philippe, White, John, Dick, Florian, Fitridge, Robert, Mills, Joseph, Ricco, Jean-Baptiste, Suresh, Kalkunte, Murad, M Hassan, Aboyans, Victor, Aksoy, Murat, Alexandrescu, Vlad-Adrian, Armstrong, David, Azuma, Nobuyoshi, Belch, Jill, Bergoeing, Michel, Bjorck, Martin, Chakfé, Nabil, Cheng, Stephen, Dawson, Joseph, Debus, Eike, Dueck, Andrew, Duval, Susan, Eckstein, Hans, Ferraresi, Roberto, Gambhir, Raghvinder, Garguilo, Mauro, Geraghty, Patrick, Goode, Steve, Gray, Bruce, Guo, Wei, Gupta, Prem, Hinchliffe, Robert, Jetty, Prasad, Komori, Kimihiro, Lavery, Lawrence, Liang, Wei, Lookstein, Robert, Menard, Matthew, Misra, Sanjay, Miyata, Tetsuro, Moneta, Greg, Munoa Prado, Jose, Muñoz, Alberto, Paolini, Juan, Patel, Manesh, Pomposelli, Frank, Powell, Richard, Robless, Peter, Rogers, Lee, Schanzer, Andres, Schneider, Peter, Taylor, Spence, Vega de Ceniga, M., Veller, Martin, Vermassen, Frank, Wang, Jinsong, Wang, Shenming, Murad, M. Hassan, Service de cardiologie [CHU de Poitiers], Centre hospitalier universitaire de Poitiers (CHU Poitiers), Neuroépidémiologie Tropicale (NET), CHU Limoges-Institut d'Epidémiologie Neurologique et de Neurologie Tropicale-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST), Université de Limoges (UNILIM)-Université de Limoges (UNILIM), Service de cardiologie [CHU Limoges], CHU Limoges, Hôpital de Strasbourg, CHU Strasbourg, and Ottawa Hospital Research Institute [Ottawa] (OHRI)
Subjects: medicine.medical_specialty, business.industry, Endovascular surgery, 030232 urology & nephrology, Ischemia, MEDLINE, 030204 cardiovascular system & hematology, medicine.disease, 3. Good health, 03 medical and health sciences, 0302 clinical medicine, medicine, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Surgery, Cardiology and Cardiovascular Medicine, Intensive care medicine, business, ComputingMilieux_MISCELLANEOUS
Abstract: International audience
Published: 2020
Full Text: View/download PDF

13. Real Life Lessons in Peripheral Artery Disease - A Priority for Public Healthcare

Author: Jean-Baptiste Ricco, Victor Aboyans, Florian Dick, Philippe Kolh, Service de cardiologie [CHU de Poitiers], Centre hospitalier universitaire de Poitiers (CHU Poitiers), Neuroépidémiologie Tropicale (NET), CHU Limoges-Institut d'Epidémiologie Neurologique et de Neurologie Tropicale-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST), Université de Limoges (UNILIM)-Université de Limoges (UNILIM), Service de cardiologie [CHU Limoges], and CHU Limoges
Subjects: Insurance, Health, Arterial disease, business.industry, Comorbidity, Disease, 030204 cardiovascular system & hematology, medicine.disease, Public healthcare, 3. Good health, Peripheral Arterial Disease, 03 medical and health sciences, 0302 clinical medicine, Germany, medicine, Humans, Surgery, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, 030212 general & internal medicine, Medical emergency, Cardiology and Cardiovascular Medicine, business, ComputingMilieux_MISCELLANEOUS
Abstract: International audience
Published: 2020
Full Text: View/download PDF

14. [Expert consensus statement on blood pressure measurement from the French Society of Hypertension, an affiliate of the French Society of Cardiology]

Author: Thierry Denolle, Roland Asmar, Jean-Marc Boivin, Xavier Girerd, Sylvain Le Jeune, Bernard Vaisse, Yara Antakly-Hanon, Mathieu Artifoni, André Atallah, Christophe Bachelet, Nicolas Barber-Chamoux, Theodora Bejan-Angoulvant, Jacques Blacher, Romain Boulestreau, François Chantrel, Yves Dimitrov, Gérard Doll, Giselle Dugelay, Béatrice Duly-Bouhanick, Philippe Gosse, Dominique Guerrot, Faiçal Jarraya, Guillaume Lamirault, Benoit Lequeux, Marilucy Lopez-Sublet, Alain Mercier, Laurène Millet, Claire Mounier-Véhier, Jean-Jacques Mourad, Edgar Nasr, Olivier Ormezzano, Laurence Perez, Alexandre Persu, Jean Ribstein, François Silhol, Philippe Sosner, Elisabeth Steyer, Mohamed Temmar, Philippe Van De Borne, Emmanuelle Vidal-Petiot, Service de cardiologie et maladies vasculaires [Rennes] = Cardiac, Thoracic, and Vascular Surgery [Rennes], CHU Pontchaillou [Rennes], Société française d’hypertension artérielle (SFHTA), Département de médecine générale [Univ. Lorraine], Université de Lorraine (UL), Service d'Endocrinologie, Métabolisme et Prévention des Maladies Cardio-vasculaires [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital de la Timone [CHU - APHM] (TIMONE), Service de médecine interne [Nantes], Université de Nantes (UN)-Hôtel-Dieu-Centre hospitalier universitaire de Nantes (CHU Nantes), CHU Clermont-Ferrand, Université de Tours (UT), Equipe 3: EREN- Equipe de Recherche en Epidémiologie Nutritionnelle (CRESS - U1153), Université Paris 13 (UP13)-Institut National de la Recherche Agronomique (INRA)-Conservatoire National des Arts et Métiers [CNAM] (CNAM), HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)), Institut National de la Recherche Agronomique (INRA)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de la Recherche Agronomique (INRA)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Bordeaux (UB), Centre Hospitalier Emile Muller [Mulhouse] (CH E.Muller Mulhouse), Groupe Hospitalier de Territoire Haute Alsace (GHTHA), Centre hospitalier de Haguenau, Hôpital Saint-André, Service de Néphrologie [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Endothélium, valvulopathies et insuffisance cardiaque (EnVI), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Sfax - University of Sfax, Unité de recherche de l'institut du thorax (ITX-lab), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Service de cardiologie [CHU de Poitiers], Centre hospitalier universitaire de Poitiers (CHU Poitiers), Hôpital cardiologique, Université de Lille, Droit et Santé-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Hôpital Avicenne [AP-HP], Clinique Cardiologie et Hypertension Artérielle, Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-Hôpital Michallon, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), Cliniques Universitaires Saint-Luc [Bruxelles], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Laboratoire 'Mobilité, Vieillissement, Exercice' (MOVE) (MOVE), Université de Poitiers, Hôpital Erasme [Bruxelles] (ULB), Faculté de Médecine [Bruxelles] (ULB), Université libre de Bruxelles (ULB)-Université libre de Bruxelles (ULB), Paris-Centre de Recherche Cardiovasculaire (PARCC - UMR-S U970), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), AP-HP - Hôpital Bichat - Claude Bernard [Paris], and Guerrot, Dominique
Subjects: medicine.medical_specialty, Evening, [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, business.industry, General Medicine, 030204 cardiovascular system & hematology, Sitting, 3. Good health, 03 medical and health sciences, Orthostatic vital signs, Masked Hypertension, 0302 clinical medicine, Blood pressure, Drug control, Ambulatory, Physical therapy, Medicine, Observational study, 030212 general & internal medicine, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract: International audience; Since 2016, the French Society of Hypertension has warned about the decline in the management of high blood pressure in France: stagnation, or even decreased number of people who know their blood pressure level, take a treatment and are controlled. These results are lower than those observed in many other countries. Blood pressure is measured with an old method in the doctor's office. Accepted, simple and cost-effective, this method is currently unavoidable for reasons of feasibility and social habit. It has been used in observational and intervention studies that are the basis of the medical reasoning for screening, treatment and drug control of hypertension. In practice, it is too often poorly applied and unpredictable. It is now necessary to measure blood pressure in mmHg using a validated oscillometric automatic device coupled to a specific upper arm cuff adapted to the arm circumferences for the diagnosis and monitoring of high blood pressure in the doctor's office and at home. The auscultatoric measurement is only recommended if any doubt about the reliability of the electronic measurement. Blood pressure measurement is basically performed on both arms to detect asymmetry and then on the arm with the highest blood pressure. It is performed in sitting or lying position after a few minutes of rest without speaking and without having smoked and then in standing position to diagnose orthostatic hypotension, especially in elderly, diabetic and multi-medicated subjects. The blood pressure measurement during the consultation must be repeated and include at least 3 consecutive measurements at one minute intervals. The average of the last 2 measurements determines the blood pressure level. It is recommended to perform BP measurements outside the medical environment for the diagnosis and monitoring of hypertension; Home BP measurement is preferred to ambulatory blood pressure measurement for practical reasons unless otherwise specified. The home blood pressure measurement should include three measurements in the morning at breakfast and three measurements in the evening before bedtime at one minute intervals for at least three days. Prior training must be provided. In treated hypertensive patients, a masked hypertension should be considered as an uncontrolled hypertension and antihypertensive therapy adapted accordingly. The measurement of central BP pressure (aorta) should be limited to clinical research.
Published: 2019
Full Text: View/download PDF

15. Editor's Choice – Follow-up of Patients After Revascularisation for Peripheral Arterial Diseases: A Consensus Document From the European Society of Cardiology Working Group on Aorta and Peripheral Vascular Diseases and the European Society for Vascular Surgery

Author: Marco De Carlo, Lucia Mazzolai, Tina Cohnert, Ileana Desormais, Ross Naylor, Serge Kownator, Jean-Baptiste Ricco, Victor Aboyans, Christine Espinola-Klein, Marianne Brodmann, Muriel Sprynger, Martin Björck, Maarit Venermo, Charalambos Vlachopoulos, GIGA Cardiovascular Sciences [Liège, Belgium] (Department of Cardiology), University Hospital Sart Tilman [Liège, Belgium]-Heart Valve Clinic [Liège, Belgium], Service de Chirurgie Thoracique et Vasculaire - Médecine vasculaire [CHU Limoges], CHU Limoges, Neuroépidémiologie Tropicale (NET), CHU Limoges-Institut d'Epidémiologie Neurologique et de Neurologie Tropicale-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST), Université de Limoges (UNILIM)-Université de Limoges (UNILIM), Uppsala Universitet [Uppsala], Centre Hospitalier Universitaire Vaudois [Lausanne] (CHUV), Service de cardiologie [CHU de Poitiers], Centre hospitalier universitaire de Poitiers (CHU Poitiers), Service de cardiologie [CHU Limoges], Verisuonikirurgian yksikkö, HUS Abdominal Center, and University of Helsinki
Subjects: Disease, 030204 cardiovascular system & hematology, 030230 surgery, Postoperative Complications, 0302 clinical medicine, Restenosis, Recurrence, Secondary Prevention, follow-up, Randomized Controlled Trials as Topic, Ultrasonography, Doppler, Duplex, medicine.diagnostic_test, 3. Good health, Europe, Systematic review, Practice Guidelines as Topic, IN-STENT RESTENOSIS, Cardiology, Cardiology and Cardiovascular Medicine, Vascular Surgical Procedures, Reoperation, medicine.medical_specialty, Consensus, Revascularisation, INFRAINGUINAL VEIN BYPASS, MEDLINE, Physical examination, STENOSIS, 03 medical and health sciences, restenosis, peripheral arterial disease, Internal medicine, medicine, Humans, ANGIOPLASTY, VELOCITY CRITERIA, business.industry, Magnetic resonance imaging, NATURAL-HISTORY, Perioperative, Vascular surgery, 3126 Surgery, anesthesiology, intensive care, radiology, medicine.disease, DUPLEX ULTRASOUND SURVEILLANCE, ENDOVASCULAR TREATMENT, RISK-FACTORS, Surgery, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, CAROTID-ARTERY, business
Abstract: International audience; Peripheral arterial diseases comprise different clinical presentations, from cerebrovascular disease down to lower extremity artery disease, from subclinical to disabling symptoms and events. According to clinical presentation, the patient's general condition, anatomical location and extension of lesions, revascularisation may be needed in addition to best medical treatment. The 2017 European Society of Cardiology guidelines in collaboration with the European Society for Vascular Surgery have addressed the indications for revascularisation. While most cases are amenable to either endovascular or surgical revascularisation, maintaining long-term patency is often challenging. Early and late procedural complications, but also local and remote recurrences frequently lead to revascularisation failure. The rationale for surveillance is to propose the accurate implementation of preventive strategies to avoid other cardiovascular events and disease progression and avoid recurrence of symptoms and the need for redo revascularisation. Combined with vascular history and physical examination, duplex ultrasound scanning is the pivotal imaging technique for identifying revascularisation failures. Other non-invasive examinations (ankle and toe brachial index, computed tomography scan, magnetic resonance imaging) at regular intervals can optimise surveillance in specific settings. Currently, optimal revascularisation surveillance programmes are not well defined and systematic reviews addressing long-term results after revascularisation are lacking. We have systematically reviewed the literature addressing follow-up after revascularisation and we propose this consensus document as a complement to the recent guidelines for optimal surveillance of revascularised patients beyond the perioperative period.
Published: 2019
Full Text: View/download PDF

16. Prognosis of Streptococcus pneumoniae endocarditis in France, a multicenter observational study (2000–2015)

Author: Pierre Tattevin, Blandine Rammaert, M. Puyade, David Boutoille, Allal J, Matthieu Revest, Amandine Périer, Adrien Lemaignen, Louis Bernard, Médecine interne [ Poitiers], Centre hospitalier universitaire de Poitiers (CHU Poitiers), Université de Poitiers - Faculté de Médecine et de Pharmacie, Université de Poitiers, Université de Rennes (UNIV-RENNES), Service des maladies infectieuses et réanimation médicale [Rennes] = Infectious Disease and Intensive Care [Rennes], CHU Pontchaillou [Rennes], Service de Médecine Interne et Maladies Infectieuses [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Université de Nantes (UN), Service de maladies infectieuses et tropicales [Nantes], Université de Nantes (UN)-Hôtel-Dieu-Centre hospitalier universitaire de Nantes (CHU Nantes), Service de cardiologie [CHU de Poitiers], Service des maladies infectieuses [Poitiers], Pharmacologie des anti-infectieux (PHAR), Université de Poitiers-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Rennes (UR), CCSD, Accord Elsevier, and Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS)
Subjects: Male, medicine.medical_specialty, [SDV]Life Sciences [q-bio], Pneumococcus vaccination, 030204 cardiovascular system & hematology, medicine.disease_cause, Pneumococcal Infections, Pneumococcal Vaccines, 03 medical and health sciences, 0302 clinical medicine, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Internal medicine, Streptococcus pneumoniae, medicine, Endocarditis, Humans, 030212 general & internal medicine, Risk factor, Cardiac Surgical Procedures, Survival rate, Retrospective Studies, Univariate analysis, business.industry, Incidence, Retrospective cohort study, Endocarditis, Bacterial, Middle Aged, [SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciences, medicine.disease, Prognosis, [SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology, 3. Good health, Cardiac surgery, Anti-Bacterial Agents, Survival Rate, [SDV] Life Sciences [q-bio], [SDV.SP] Life Sciences [q-bio]/Pharmaceutical sciences, Infective endocarditis, [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Female, France, [SDV.MP.BAC] Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology, Cardiology and Cardiovascular Medicine, business, Follow-Up Studies, Forecasting
Abstract: International audience; Background: Streptococcus pneumoniae is responsible for
Published: 2019
Full Text: View/download PDF

17. Targeted panel sequencing in adult patients with left ventricular non-compaction reveals a large genetic heterogeneity

Author: Pascale Richard, Anne-Claire Casalta, Karine Nguyen, Laurence Faivre, Nicolas Mansencal, Gilbert Habib, Flavie Ader, Maguelonne Roux, Philippe Charron, Cécile Lavoute, Nadia Aoutil, Thibaud Damy, Erwan Donal, Damien Coisne, Jean-Christophe Eicher, David-Alexandre Trégouët, Julie Haentjens, Guillaume Jondeau, Nicolas Michel, Christine Selton-Suty, Olivier Huttin, CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] (IHU ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Pitié-Salpêtrière [AP-HP], CHU Pontchaillou [Rennes], Service de Cardiologie [CHU de Dijon], Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Service de Cardiologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Service de cardiologie [CHU de Poitiers], Centre hospitalier universitaire de Poitiers (CHU Poitiers), AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Henri Mondor [Créteil], Hôpital Ambroise Paré [AP-HP], Département de Cardiologie [Hôpital de la Timone - APHM], Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), CHU Dijon, Marseille medical genetics - Centre de génétique médicale de Marseille (MMG), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Hospitalier Universitaire Méditerranée Infection (IHU Marseille), Microbes évolution phylogénie et infections (MEPHI), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Unité Fonctionnelle de Cardiogénétique et Myogénétique Moléculaire et Cellulaire, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Service de Biochimie Métabolique [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Institute of cardiometabolism and nutrition (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], CHU Henri Mondor, Hôpital de la Timone [CHU - APHM] (TIMONE)-Assistance Publique - Hôpitaux de Marseille (APHM), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Aix Marseille Université (AMU)
Subjects: Adult, Male, 0301 basic medicine, Candidate gene, Genotype, Genetic counseling, Cardiomyopathy, 030105 genetics & heredity, Biology, left ventricular non-compaction, medicine.disease_cause, Genetic Heterogeneity, Ventricular Dysfunction, Left, 03 medical and health sciences, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, molecular genetic, Genetics, medicine, Humans, Genetic Predisposition to Disease, Allele, Alleles, Genetic Association Studies, Genetics (clinical), next generation sequencing, Mutation, [SDV.GEN.GPO]Life Sciences [q-bio]/Genetics/Populations and Evolution [q-bio.PE], Genetic heterogeneity, Computational Biology, Genetic Variation, High-Throughput Nucleotide Sequencing, Middle Aged, medicine.disease, Pedigree, 3. Good health, Phenotype, 030104 developmental biology, [SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human genetics, Echocardiography, Female, MYH7, Cardiomyopathies, cardiomyopathy, Biomarkers
Abstract: International audience; Left ventricular non-compaction (LVNC) is a cardiomyopathy that may be of genetic origin; however, few data are available about the yield of mutation, the spectrum of genes and allelic variations. The aim of this study was to better characterize the genetic spectrum of isolated LVNC in a prospective cohort of 95 unrelated adult patients through the molecular investigation of 107 genes involved in cardiomyopathies and arrhythmias. Fifty-two pathogenic or probably pathogenic variants were identified in 40 patients (42%) including 31 patients (32.5%) with single variant and 9 patients with complex genotypes (9.5%). Mutated patients tended to have younger age at diagnosis than patients with no identified mutation. The most prevalent genes were TTN, then HCN4, MYH7, and RYR2. The distribution includes 13 genes previously reported in LVNC and 10 additional candidate genes. Our results show that LVNC is basically a genetic disease and support genetic counseling and cardiac screening in relatives. There is a large genetic heterogeneity, with predominant TTN null mutations and frequent complex genotypes. The gene spectrum is close to the one observed in dilated cardiomyopathy but with specific genes such as HCN4. We also identified new candidate genes that could be involved in this sub-phenotype of cardiomyopathy.
Published: 2019
Full Text: View/download PDF

18. Stress response in the daily lives of simulation repeaters. A randomized controlled trial assessing stress evolution over one year of repetitive immersive simulations

Author: Denis Oriot, Jean-Jacques Chavagnat, Mathieu Lesbordes, Cyril Breque, Philippe Sosner, Daniel Aiham Ghazali, Stéphanie Ragot, Bodescot, Myriam, Emergency Department [Paris], AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Emergency Medical Service [Paris], Laboratoire Universitaire Médical d’Enseignement basé sur les technologies Numériques et de Simulation (iLumens - site Paris 7), Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC), Laboratoire d’Anatomie, Biomécanique et Simulation (ABS Lab), Université de Poitiers - Faculté de Médecine et de Pharmacie, Université de Poitiers-Université de Poitiers-Université de Poitiers - Faculté de Sciences fondamentales et appliquées, Université de Poitiers, Diagnosis and Therapeutic Center [Paris], Hôpital Hôtel-Dieu [Paris], Service de cardiologie [CHU de Poitiers], Centre hospitalier universitaire de Poitiers (CHU Poitiers), Adult Psychiatric Unit [Poitiers], CIC - Poitiers, Université de Poitiers-Centre hospitalier universitaire de Poitiers (CHU Poitiers)-Direction Générale de l'Organisation des Soins (DGOS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Pediatric Emergency Department [Poitiers], and DA Ghazali was the recipient of a grant from the French Emergency Medicine Society (SFMU). The commercial company Laerdal (Tanke Svilandsgt 30. Stavanger, 4002. Norway) provided the SFMU with the amount of the grant.
Subjects: Male, Emergency Medical Services, Periodicity, Critical Care and Emergency Medicine, Sympathetic Nervous System, Medical Doctors, Physiology, Health Care Providers, [SDV.MHEP.PSM] Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, Social Sciences, Nervous System, Pediatrics, Session (web analytics), law.invention, Stress Disorders, Post-Traumatic, 0302 clinical medicine, Randomized controlled trial, Multidisciplinary approach, law, Heart Rate, Recurrence, Risk Factors, Activities of Daily Living, Emergency medical services, Medicine and Health Sciences, Medicine, Heart rate variability, Psychology, Medical Personnel, Lead (electronics), Multidisciplinary, Post-Traumatic Stress Disorder, Anxiety Disorders, Circadian Rhythm, Electrophysiology, Professions, Disease Progression, Female, [SDV.IB]Life Sciences [q-bio]/Bioengineering, Anatomy, Psychopathology, Research Article, Adult, medicine.medical_specialty, Critical Care, Science, Cardiology, Psychological Stress, Neuropsychiatric Disorders, Neuroses, Autonomic Nervous System, 03 medical and health sciences, 030225 pediatrics, Physicians, Heart rate, Mental Health and Psychiatry, Peripheral Nervous System, Humans, Simulation Training, [SDV.IB] Life Sciences [q-bio]/Bioengineering, business.industry, Biology and Life Sciences, 030208 emergency & critical care medicine, Health Care, [SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, People and Places, Physical therapy, Population Groupings, business, Stress, Psychological
Abstract: BackgroundSimulations in healthcare reproduce clinical situations in stressful conditions. Repeated stress exposure might influence the learning process in simulation as well as real-life.Objectives1) To record heart rate and heart rate variability evolution during one-day simulation over one year; 2) To analyze the effect of repetitive high-fidelity simulations on the risk of post-traumatic stress disorder.Study designSingle-center, investigator-initiated RCT. 48 participants were randomized in 12 multidisciplinary teams of French Emergency Medical Services to manage infant shock in high-fidelity simulations. In the experimental group, 6 multidisciplinary teams were exposed to 9 different simulation sessions over 1 year. In the control group, 6 multidisciplinary teams participated in only 3 simulation sessions, in common with those of the experimental group (initial, intermediate after 6 months, and finally after 1 year). Heart rate (HR) and heart rate variability (HRV) were analyzed on a 24-hour Holter from the day prior to simulation until the end of simulation. Questionnaires of Impact of Event Scale-Revised at 7 days and Post-traumatic Check-List Scale at 1 month were used to detect possible post-traumatic stress disorder in participants. pResultsStress increased during each simulation in the two groups. After analysis on the 24-hour period, there was no significant difference between the two groups during the initial simulation session in terms of heart rate and heart rate variability. In the 24-hour period of the intermediate and final simulation sessions, the level of stress was higher in the control group during the diurnal (p = 0.04) and nocturnal periods (p = 0.01). No participant developed post-traumatic stress disorder after the 72 simulation sessions.ConclusionsDespite the stress generated by simulation, the more the sessions were repeated, the less were their repercussions on the daily lives of participants, reflected by a lower sympathetic activity. Moreover, repetition of simulations did not lead to post-traumatic stress disorder.Trial registrationClinicalTrials.gov NCT02424890.
Published: 2019
Full Text: View/download PDF

19. Targeted panel sequencing and allelic spectrum in 95 unrelated adults with left ventricular non-compaction

Author: Richard, P., Ader, F., Roux, M., Donal, E., Jc. Eicher, Olivier Huttin, Damien Coisne, Guillaume Jondeau, Thibaud Damy, Nicolas Mansencal, Guyen, Karine N., CECILE LAVOUTE, David-Alexandre Tregouet, Gilbert Habib, Philippe Charron, CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] (IHU ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Pitié-Salpêtrière [AP-HP], CHU Pontchaillou [Rennes], Service de Cardiologie [CHU de Dijon], Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Service de Cardiologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Service de cardiologie [CHU de Poitiers], Centre hospitalier universitaire de Poitiers (CHU Poitiers), AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Unité fonctionnelle insuffisance cardiaque, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est (UPE), Hôpital Ambroise Paré [AP-HP], Département de génétique médicale [Hôpital de la Timone - APHM], Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE)-Institut National de la Santé et de la Recherche Médicale (INSERM), Département de Cardiologie [Hôpital de la Timone - APHM], Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Microbes évolution phylogénie et infections (MEPHI), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Assistance Publique - Hôpitaux de Marseille (APHM), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Institute of cardiometabolism and nutrition (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Hosp Pontchaillou Rennes, Hôpital de la Timone [CHU - APHM] (TIMONE)-Assistance Publique - Hôpitaux de Marseille (APHM), and Assistance Publique-Hôpitaux de Marseille (AP-HM)
Subjects: [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, [SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology, [SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology, ComputingMilieux_MISCELLANEOUS
Abstract: International audience
Published: 2018

20. Circulating Concentrations of Redox Biomarkers Do Not Improve the Prediction of Adverse Cardiovascular Events in Patients With Type 2 Diabetes Mellitus

Author: Cournot, Maxime, Burillo, Elena, Saulnier, Pierre-Jean, Planesse, Cynthia, Gand, Elise, Rehman, Michaela, Gonthier, Marie-Paule, Ragot, Stéphanie, Rondeau, Philippe, Catan, Aurélie, Feigerlova, Eva, Meilhac, Olivier, Hadjadj, Samy, Diabète athérothrombose et thérapies Réunion Océan Indien (DéTROI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de La Réunion (UR), Centre d'Investigation Clinique de La Réunion - INSERM (CIC 1410), Université de La Réunion (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de La Réunion (CHU La Réunion), CIC - Poitiers, Université de Poitiers-Centre hospitalier universitaire de Poitiers (CHU Poitiers)-Direction Générale de l'Organisation des Soins (DGOS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Poitiers - Faculté de Médecine et de Pharmacie, Université de Poitiers, Pôle DUNE, Centre hospitalier universitaire de Poitiers (CHU Poitiers), Service de cardiologie [CHU de Poitiers], Ischémie Reperfusion en Transplantation d’Organes Mécanismes et Innovations Thérapeutiques ( IRTOMIT), Université de Poitiers-Institut National de la Santé et de la Recherche Médicale (INSERM), Service Endocrinologie [CHU Poitiers], Univ, Réunion, and Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Poitiers
Subjects: 0301 basic medicine, Oncology, Glycation End Products, Advanced, Male, Time Factors, cardiovascular outcome, 030204 cardiovascular system & hematology, Protein Carbonylation, 0302 clinical medicine, Risk Factors, Cardiovascular Disease, oxidative stress, Myocardial infarction, Prospective Studies, Preventive Cardiology, Prospective cohort study, Original Research, Univariate analysis, Hazard ratio, Diabetes, Type 2, Middle Aged, Prognosis, 3. Good health, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Advanced Oxidation Protein Products, Cardiovascular Diseases, diabetes mellitus, Female, Cardiology and Cardiovascular Medicine, Oxidation-Reduction, Cohort study, medicine.medical_specialty, Serum Albumin, Human, Hemolysis, Risk Assessment, 03 medical and health sciences, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Predictive Value of Tests, Internal medicine, Diabetes mellitus, medicine, cohort study, Humans, cardiovascular diseases, Aged, business.industry, Type 2 Diabetes Mellitus, biomarkers, medicine.disease, 030104 developmental biology, Diabetes Mellitus, Type 2, negative study, business, Mace
Abstract: Background Despite pathophysiological relevance and promising experimental data, the usefulness of biomarkers of oxidative stress for cardiac risk prediction is unclear. The aim of our study was to investigate the prognostic value of 6 biomarkers exploring different pathways of oxidative stress for predicting adverse cardiovascular outcomes in patients with type 2 diabetes mellitus beyond established risk factors. Methods and Results The SURDIAGENE (Survie, Diabete de type 2 et Genetique) prospective cohort study consecutively recruited 1468 patients with type 2 diabetes mellitus. Assays were performed at baseline, and incident cases of major adverse cardiovascular events ( MACE )—first occurrence of cardiovascular death, nonfatal myocardial infarction, or stroke—were recorded during a median of 64 months. Advanced oxidation protein products, oxidative hemolysis inhibition assay, ischemia‐modified albumin, and total reductive capacity of plasma were not associated with the risk of MACE in univariate analyses. Fluorescent advanced glycation end products and carbonyls were associated with MACE (hazard ratio=1.38 per SD , 95% confidence interval 1.24‐1.54, P SD , 95% confidence interval 1.04‐1.27, P =0.006, respectively) in univariate analysis, but when added to a multivariate predictive model including traditional risk factors for MACE , these markers did not significantly improve c‐statistics or integrated discrimination index of the model. Conclusions These plasma concentrations of 6 markers, which cover a broad spectrum of oxidative processes, were not significantly associated with MACE occurrence and were not able to improve MACE risk discrimination and classification beyond classical risk factors in type 2 diabetes mellitus patients.
Published: 2018
Full Text: View/download PDF

21. Editor's Choice – 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS)

Author: Aboyans, Victor, Ricco, Jean-Baptiste, Bartelink, Marie-Louise E.L., Björck, Martin, Brodmann, Marianne, Cohnert, Tina, Collet, Jean-Philippe, Czerny, Martin, De Carlo, Marco, Debus, Sebastian, Espinola-Klein, Christine, Kahan, Thomas, Kownator, Serge, Mazzolai, Lucia, Naylor, A. Ross, Roffi, Marco, Röther, Joachim, Sprynger, Muriel, Tendera, Michal, Tepe, Gunnar, Venermo, Maarit, Vlachopoulos, Charalambos, Desormais, Iléana, Widimsky, Petr, Kolh, Philippe, Agewall, Stefan, Bueno, Hector, Coca, Antonio, De Borst, Gert, Delgado, Victor, Dick, Florian, Erol, Cetin, Ferrini, Marc, Kakkos, Stavros, Katus, Hugo, Knuuti, Juhani, Lindholt, Jes, Mattle, Heinrich, Pieniazek, Piotr, Piepoli, Massimo Francesco, Scheinert, Dierk, Sievert, Horst, Simpson, Iain, Sulzenko, Jakub, Tamargo, Juan, Tokgözoglu, Lale, Torbicki, Adam, Tsakountakis, Nikolaos, Tuñón, José, de Ceniga, Melina Vega, Windecker, Stephan, Zamorano, Jose Luis, Service de Chirurgie Thoracique et Vasculaire - Médecine vasculaire [CHU Limoges], CHU Limoges, Neuroépidémiologie Tropicale (NET), Institut Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST), Université de Limoges (UNILIM)-Université de Limoges (UNILIM)-CHU Limoges-Institut d'Epidémiologie Neurologique et de Neurologie Tropicale-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de cardiologie [CHU de Poitiers], Centre hospitalier universitaire de Poitiers (CHU Poitiers), Department of Internal Medicine, Medizinische Universität Graz, Institut de cardiologie [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet [Stockholm], Department of Neurology, Asklepios Klinik Altona, Centre Hospitalier Universitaire de Liège (CHU-Liège), Third Division of Cardiology, Medical University of Silesia (SUM), Karolinska Institute, karolinska institute, Hospital General Universitario 'Gregorio Marañón' [Madrid], Heidelberg University Hospital [Heidelberg], Turku PET Centre, University of Turku, Universidad Complutense de Madrid = Complutense University of Madrid [Madrid] (UCM), Hacettepe University = Hacettepe Üniversitesi, Universidad de Alcalá - University of Alcalá (UAH), CHU Limoges-Institut d'Epidémiologie Neurologique et de Neurologie Tropicale-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST), Université de Limoges (UNILIM)-Université de Limoges (UNILIM), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), and Medical University of Silesia
Subjects: [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, ComputingMilieux_MISCELLANEOUS
Abstract: International audience
Published: 2018

22. Questions and answers on diagnosis and management of patients with Peripheral Arterial Diseases: a companion document of the 2017 ESC Guidelines for the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS)

Author: Aboyans, Victor, Björck, Martin, Brodmann, Marianne, Collet, Jean-Philippe, Czerny, Martin, De Carlo, Marco, Naylor, A Ross, Roffi, Marco, Tendera, Michal, Vlachopoulos, Charalambos, Ricco, Jean-Baptiste, Widimsky, Petr, Kolh, Philippe, Dick, Florian, de Ceniga, Melina Vega, Sievert, Horst, Sulzenko, Jakub, Windecker, Stephan, Agewall, Stefan, Barbato, Emanuele, Bueno, Hector, Coca, Antonio, Coman, Ioan Mircea, Dean, Veronica, Delgado, Victor, Fitzsimons, Donna, Gaemperli, Oliver, Hindricks, Gerhard, Iung, Bernard, Jüni, Peter, Katus, Hugo, Knuuti, Juhani, Lancellotti, Patrizio, Leclercq, Christophe, Mcdonagh, Theresa, Piepoli, Massimo Francesco, Ponikowski, Piotr, Richter, Dimitrios, Shlyakhto, Evgeny, Simpson, Iain, Zamorano, Jose Luis, Bartelink, Marie-Louise EL, Cohnert, Tina, Debus, Sebastian, Espinola-Klein, Christine, Kahan, Thomas, Kownator, Serge, Mazzolai, Lucia, Röther, Joachim, Sprynger, Muriel, Tepe, Gunnar, Venermo, Maarit, Desormais, Iléana, Service de Chirurgie Thoracique et Vasculaire - Médecine vasculaire [CHU Limoges], CHU Limoges, Neuroépidémiologie Tropicale (NET), Institut Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST), Université de Limoges (UNILIM)-Université de Limoges (UNILIM)-CHU Limoges-Institut d'Epidémiologie Neurologique et de Neurologie Tropicale-Institut National de la Santé et de la Recherche Médicale (INSERM), Department of Internal Medicine, Medizinische Universität Graz, Institut de cardiologie [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Third Division of Cardiology, Medical University of Silesia (SUM), Service de cardiologie [CHU de Poitiers], Centre hospitalier universitaire de Poitiers (CHU Poitiers), Karolinska Institute, karolinska institute, 'Federico II' University of Naples Medical School, Hospital General Universitario 'Gregorio Marañón' [Madrid], CHU de Montpellier, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), St. Michael's Hospital, Heidelberg University Hospital [Heidelberg], Turku PET Centre, University of Turku, Wroclaw Medical University, Universidad de Alcalá - University of Alcalá (UAH), Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet [Stockholm], Centre Hospitalier Universitaire de Liège (CHU-Liège), CHU Limoges-Institut d'Epidémiologie Neurologique et de Neurologie Tropicale-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST), Université de Limoges (UNILIM)-Université de Limoges (UNILIM), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), and Medical University of Silesia
Subjects: Aged, 80 and over, Male, Arterial Occlusive Diseases, Coronary Artery Disease, Intermittent Claudication, Middle Aged, 030204 cardiovascular system & hematology, ta3121, Atherosclerosis, 3. Good health, Peripheral Arterial Disease, 03 medical and health sciences, 0302 clinical medicine, Practice Guidelines as Topic, Vertebrobasilar Insufficiency, Humans, Female, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Cardiology and Cardiovascular Medicine, Diabetic Angiopathies, 030217 neurology & neurosurgery, ComputingMilieux_MISCELLANEOUS, Aged
Abstract: International audience
Published: 2018
Full Text: View/download PDF

23. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS)

Author: Ricco, Jean-Baptiste, Bartelink, Marie-Louise, Björck, Martin, Brodmann, Marianne, Cohnert, Tina, Czerny, Martin, De Carlo, Marco, Debus, Sebastian, Espinola-Klein, Christine, Kahan, Thomas, Kownator, Serge, Mazzolai, Lucia, Naylor, A Ross, Röther, Joachim, Sprynger, Muriel, Tendera, Michal, Tepe, Gunnar, Venermo, Maarit, Vlachopoulos, Charalambos, Desormais, Iléana, Widimsky, Petr, Kolh, Philippe, De Borst, Gert, Dick, Florian, Erol, Cetin, Ferrini, Marc, Kakkos, Stavros, Lindholt, Jes, Mattle, Heinrich, Pieniazek, Piotr, Scheinert, Dierk, Sievert, Horst, Sulzenko, Jakub, Tamargo, Juan, Tokgözoglu, Lale, Torbicki, Adam, Tsakountakis, Nikolaos, Tuñón, José, de Ceniga, Melina Vega, Windecker, Stephan, Aboyans, Victor, Agewall, Stefan, Barbato, Emanuele, Bueno, Hector, Coca, Antonio, Collet, Jean-Philippe, Coman, Ioan Mircea, Dean, Veronica, Delgado, Victor, Fitzsimons, Donna, Gaemperli, Oliver, Hindricks, Gerhard, Iung, Bernard, Jüni, Peter, Katus, Hugo, Knuuti, Juhani, Lancellotti, Patrizio, Leclercq, Christophe, Mcdonagh, Theresa, Piepoli, Massimo Francesco, Ponikowski, Piotr, Richter, Dimitrios, Roffi, Marco, Shlyakhto, Evgeny, Simpson, Iain, Zamorano, Jose Luis, Zelveian, Parounak, Haumer, Markus, Isachkin, Dzmitry, De Backer, Tine, Dilic, Mirza, Petrov, Petr, Kirhmajer, Majda Vrkic, Karetova, Debora, Prescott, Eva, Soliman, Hamdy, Paapstel, Ants, Makinen, Kimmo, Tosev, Slavco, Messas, Emmanuel, Pagava, Zurab, Müller, Oliver, Naka, Katerina, Járai, Zoltán, Gudjonsson, Thorbjorn, Jonas, Michael, Novo, Salvatore, Ibrahimi, Pranvera, Lunegova, Olga, Dzerve, Vilnis, Misonis, Nerijus, Beissel, Jean, Pllaha, Elton, Taberkant, Mustapha, Bakken, Torbjørn, Teles, Rui, Lighezan, Daniel, Konradi, Alexandra, Zavatta, Marco, Madaric, Juraj, Fras, Zlatko, Melchor, Lorenzo Silva, Näslund, Ulf, Amann-Vesti, Beatrice, Obiekezie, Agu, Service de cardiologie [CHU de Poitiers], Centre hospitalier universitaire de Poitiers (CHU Poitiers), Julius Centre for Health Sciences and Primary Health Care, Department of Internal Medicine, Medizinische Universität Graz, Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet [Stockholm], Department of Neurology, Asklepios Klinik Altona, Centre Hospitalier Universitaire de Liège (CHU-Liège), Third Division of Cardiology, Medical University of Silesia (SUM), Service de Chirurgie Thoracique et Vasculaire - Médecine vasculaire [CHU Limoges], CHU Limoges, Neuroépidémiologie Tropicale (NET), Institut Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST), Université de Limoges (UNILIM)-Université de Limoges (UNILIM)-CHU Limoges-Institut d'Epidémiologie Neurologique et de Neurologie Tropicale-Institut National de la Santé et de la Recherche Médicale (INSERM), Hacettepe University = Hacettepe Üniversitesi, Karolinska Institute, karolinska institute, 'Federico II' University of Naples Medical School, Hospital General Universitario 'Gregorio Marañón' [Madrid], Institut de cardiologie [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), CHU de Montpellier, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), St. Michael's Hospital, Heidelberg University Hospital [Heidelberg], Turku PET Centre, University of Turku, Wroclaw Medical University, Universidad de Alcalá - University of Alcalá (UAH), Paris-Centre de Recherche Cardiovasculaire (PARCC - UMR-S U970), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Michaelid Cardiac Ctr, University of Ioannina, Medical University of Silesia, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Pitié-Salpêtrière [APHP], Université Paris Descartes - Paris 5 (UPD5)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Limoges-Institut d'Epidémiologie Neurologique et de Neurologie Tropicale-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST), Université de Limoges (UNILIM)-Université de Limoges (UNILIM), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Hôpital Européen Georges Pompidou [APHP] (HEGP), and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Subjects: [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, ComputingMilieux_MISCELLANEOUS
Abstract: International audience
Published: 2018

24. Abdominal aortic calcifications influences the systemic and renal hemodynamic response to renal denervation in the denerhtn (renal denervation for hypertension) trial

Author: Pierre-Yves, Courand, Helena, Pereira, Costantino, Del Giudice, Philippe, Gosse, Matthieu, Monge, Guillaume, Bobrie, Pascal, Delsart, Claire, Mounier-Vehier, Pierre, Lantelme, Thierry, Denolle, Caroline, Dourmap, Jean Michel, Halimi, Xavier, Girerd, Patrick, Rossignol, Faiez, Zannad, Olivier, Ormezzano, Bernard, Vaisse, Daniel, Herpin, Jean, Ribstein, Beatrice, Bouhanick, Jean-Jacques, Mourad, Emile, Ferrari, Gilles, Chatellier, Marc, Sapoval, Arshid, Azarine, Michel, Azizi, A, Persu, CHU Lille, Université de Lille, Hôpital de la Croix-Rousse [CHU - HCL], METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694, Hôpital Européen Georges Pompidou [APHP] [HEGP], Hôpital Saint-André, Institut Mutualiste de Montsouris [IMM], Centre Hospitalier Régional Universitaire [Lille] [CHRU Lille], Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS], Service de cardiologie et maladies vasculaires [Rennes] = Cardiac, Thoracic, and Vascular Surgery [Rennes], CHU Pitié-Salpêtrière [AP-HP], Centre Hospitalier Régional Universitaire de Nancy [CHRU Nancy], CHU Grenoble, Hôpital de la Timone [CHU - APHM] [TIMONE], Service de cardiologie [CHU de Poitiers], Université de Montpellier [UM], Hôpital Avicenne [AP-HP], Hôpital Pasteur [Nice] [CHU], Herrada, Anthony, Hospices Civils de Lyon (HCL), Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé (CREATIS), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Hospices Civils de Lyon (HCL)-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), CIC - HEGP (CIC 1418), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Service de radiologie cardio-vasculaire [CHU HEGP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Institut Mutualiste de Montsouris (IMM), Service de médecine vasculaire et hypertension artérielle [CHU HEGP], Hôpital cardiologique, Université de Lille, Droit et Santé-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), CHU Pontchaillou [Rennes], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre d'investigation clinique [Nancy] (CIC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Défaillance Cardiovasculaire Aiguë et Chronique (DCAC), Hôpital de la Timone [CHU - APHM] (TIMONE), Centre hospitalier universitaire de Poitiers (CHU Poitiers), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Université de Montpellier (UM), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Hôpital Pasteur [Nice] (CHU), Université Paris Descartes - Paris 5 (UPD5), Université Jean Monnet [Saint-Étienne] (UJM)-Hospices Civils de Lyon (HCL)-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital de Rangueil, CHU Toulouse [Toulouse], and Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université de Lyon-Université Claude Bernard Lyon 1 (UCBL)
Subjects: Male, Time Factors, Computed Tomography Angiography, Kidney, resistant hypertension, renal denervation, aortic calcification, antihypertensive therapy/sympathetic nervous system, atherosclerosis, aortic disease, Renal Artery, Vascular Disease, Aorta, Abdominal, Prospective Studies, Original Research, Middle Aged, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Treatment Outcome, Hypertension, Female, France, Glomerular Filtration Rate, Adult, Aortic Diseases, Aortography, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Multidetector Computed Tomography, Humans, Arterial Pressure, Sympathectomy, Vascular Calcification, Antihypertensive Agents, Aged, Treatment
Abstract: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01570777.; International audience; BACKGROUND : The DENERHTN (Renal Denervation for Hypertension) trial confirmed the efficacy of renal denervation (RDN) in lowering daytime ambulatory systolic blood pressure when added to standardized stepped-care antihypertensive treatment (SSAHT) for resistant hypertension at 6 months.METHODS AND RESULTS : This post hoc exploratory analysis assessed the impact of abdominal aortic calcifications (AAC) on the hemodynamic and renal response to RDN at 6 months. In total, 106 patients with resistant hypertension were randomly assigned to RDN plus SSAHT or to the same SSAHT alone (control group). Total AAC volume was measured, with semiautomatic software and blind to randomization, from the aortic hiatus to the iliac bifurcation using the prerandomization noncontrast abdominal computed tomography scans of 90 patients. Measurements were expressed as tertiles. The baseline-adjusted difference in the change in daytime ambulatory systolic blood pressure from baseline to 6 months between the RDN and control groups was -10.1 mm Hg (P=0.0462) in the lowest tertile and -2.5 mm Hg (P=0.4987) in the 2 highest tertiles of AAC volume. Estimated glomerular filtration rate remained stable at 6 months for the patients in the lowest tertile of AAC volume who underwent RDN (+2.5 mL/min per 1.73 m2) but decreased in the control group (-8.0 mL/min per 1.73 m2, P=0.0148). In the 2 highest tertiles of AAC volume, estimated glomerular filtration rate decreased similarly in the RDN and control groups (P=0.2640).CONCLUSIONS : RDN plus SSAHT resulted in a larger decrease in daytime ambulatory systolic blood pressure than SSAHT alone in patients with a lower AAC burden than in those with a higher AAC burden. This larger decrease in daytime ambulatory systolic blood pressure was not associated with a decrease in estimated glomerular filtration rate.
Published: 2017
Full Text: View/download PDF

25. Twenty-Four-Hour Blood Pressure Monitoring to Predict and Assess Impact of Renal DenervationNovelty and Significance

Author: Gosse, Philippe, Cremer, Antoine, Pereira, Helena, Bobrie, Guillaume, Chatellier, Gilles, Chamontin, Bernard, Courand, Pierre, Delsart, Pascal, Denolle, Thierry, Dourmap, Caroline, Ferrari, Emile, Girerd, Xavier, Michel Halimi, J., Herpin, Daniel, Lantelme, Pierre, Monge, Matthieu, Mounier-Vehier, Claire, Mourad, Jean, Ormezzano, Olivier, Ribstein, Jean, Rossignol, Patrick, Sapoval, Marc, Vaisse, Bernard, Zannad, Faiez, Azizi, Michel, Hôpital Saint-André, CIC - HEGP (CIC 1418), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Université Paris Descartes - Paris 5 (UPD5), CHU Toulouse [Toulouse], Hôpital de la Croix-Rousse [CHU - HCL], Hospices Civils de Lyon (HCL), Hôpital cardiologique, Université de Lille, Droit et Santé-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Hôpital Arthur Gardiner, CHU Pontchaillou [Rennes], Centre Hospitalier Universitaire de Nice (CHU Nice), Service d’Endocrinologie, Métabolisme et Prévention des Risques Cardio-Vasculaires [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS), Cellules dendritiques, immunointervention et greffes (CDG), Université de Tours, Service de cardiologie [CHU de Poitiers], Centre hospitalier universitaire de Poitiers (CHU Poitiers), Hôpital Avicenne [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Grenoble, Radiopharmaceutiques biocliniques (LRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Cardiovascular and Renal Clinical Trialists [Vandoeuvre-les-Nancy] (INI-CRCT), Institut Lorrain du Coeur et des Vaisseaux Louis Mathieu [Nancy], Défaillance Cardiovasculaire Aiguë et Chronique (DCAC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), French-Clinical Research Infrastructure Network - F-CRIN [Paris] (Cardiovascular & Renal Clinical Trialists - CRCT ), Centre d'investigation clinique plurithématique Pierre Drouin [Nancy] (CIC-P), Centre d'investigation clinique [Nancy] (CIC), Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de radiologie cardio-vasculaire [CHU HEGP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Hôpital de la Timone [CHU - APHM] (TIMONE), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Université de Tours (UT), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Service d'endocrinologie-métabolisme [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Pitié-Salpêtrière [APHP], Hôpital avicenne, Université Paris 13 (UP13)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Avicenne, Radiopharmaceutiques biocliniques, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Grenoble Alpes (UGA), CIC-Nancy, Institut Lorrain du Coeur et des Vaisseaux Louis Mathieu [Nancy]-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Lorraine (UL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), and Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)
Subjects: ambulatory blood pressure monitoring, smoothness index, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, resistant hypertension, blood pressure variability, renal denervation
Abstract: International audience; The DENERHTN trial (Renal Denervation for Hypertension) confirmed the blood pressure (BP) lowering efficacy of renal denervation added to a standardized stepped-care antihypertensive treatment for resistant hypertension at 6 months. We report here the effect of denervation on 24-hour BP and its variability and look for parameters that predicted the BP response. Patients with resistant hypertension were randomly assigned to denervation plus stepped-care treatment or treatment alone (control). Average and standard deviation of 24-hour, daytime, and nighttime BP and the smoothness index were calculated on recordings performed at randomization and 6 months. Responders were defined as a 6-month 24-hour systolic BP reduction ≥20 mm Hg. Analyses were performed on the per-protocol population. The significantly greater BP reduction in the denervation group was associated with a higher smoothness index (P=0.02). Variability of 24-hour, daytime, and nighttime BP did not change significantly from baseline to 6 months in both groups. The number of responders was greater in the denervation (20/44, 44.5%) than in the control group (11/53, 20.8%; P=0.01). In the discriminant analysis, baseline average nighttime systolic BP and standard deviation were significant predictors of the systolic BP response in the denervation group only, allowing adequate responder classification of 70% of the patients. Our results show that denervation lowers ambulatory BP homogeneously over 24 hours in patients with resistant hypertension and suggest that nighttime systolic BP and variability are predictors of the BP response to denervation. CLINICAL TRIAL REGISTRATION : URL: https://www.clinicaltrials.gov. Unique identifier: NCT01570777
Published: 2017
Full Text: View/download PDF

26. The ambulatory hypotensive effect of aerobic training: a reappraisal through a meta-analysis of selected moderators

Author: Laurent Bosquet, Vincent Gremeaux, Denis Arvisais, Thibaut Guiraud, Daniel Herpin, Philippe Sosner, Centre EPIC [Institut de Cardiologie de Montréal], Université de Montréal (UdeM)-Montreal Heart Institute - Institut de Cardiologie de Montréal, Service de cardiologie [CHU de Poitiers], Centre hospitalier universitaire de Poitiers (CHU Poitiers), Centre médico-sportif Mon Stade [Paris], Laboratoire 'Mobilité, Vieillissement, Exercice' (MOVE) (MOVE), Université de Poitiers, Réeducation Cardio-Vasculaire et Pulmonaire [Clinique de Saint-Orens], Clinique Saint-Orens, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées, Pôle Rééducation - Réadaptation (Médecine Physique et Réadaptation) (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Cognition, Action, et Plasticité Sensorimotrice [Dijon - U1093] (CAPS), Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM), Plateforme d’Investigation Technologique [Centre d’Investigation Clinique 1432 module Plurithématique - Dijon] (PIT), Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre d'Investigation Clinique 1432 (Dijon) - Module Plurithématique : Périnatalité Cancérologie Handicap et Ophtalmologie (CIC-P803), Université de Bourgogne (UB)-Direction Générale de l'Organisation des Soins (DGOS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Direction Générale de l'Organisation des Soins (DGOS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Direction of Libraries / Direction des bibliothèques [Montréal], Université de Montréal (UdeM), Université de Poitiers - Faculté de Médecine et de Pharmacie, Université de Poitiers - Faculté des Sciences du sport, Département de Kinésiologie, Laboratoire d'Étude de la Santé Cognitive des Ainés [Montréal] (LESCA), Université du Québec à Montréal = University of Québec in Montréal (UQAM), Université de Montréal [Montréal]-Montreal Heart Institute - Institut de Cardiologie de Montréal, CHU de Poitiers, Laboratoire 'Mobilité, Vieillissement, Exercice' (MOVE) ( MOVE ), Institut des Maladies Métaboliques et Cardiovasculaires ( I2MC ), Université Paul Sabatier - Toulouse 3 ( UPS ) -Hôpital de Rangueil-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon ), Cognition, Action, et Plasticité Sensorimotrice [Dijon - U1093] ( CAPS ), Université de Bourgogne ( UB ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Plateforme d’Investigation Technologique [Centre d’Investigation Clinique 1432 module Plurithématique - Dijon] ( PIT ), Université de Bourgogne ( UB ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université de Bourgogne ( UB ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre d'Investigation Clinique 1432 (Dijon) - Module Plurithématique : Périnatalité Cancérologie Handicap et Ophtalmologie ( CIC-P803 ), Université de Bourgogne ( UB ) -Direction Générale de l'Organisation des Soins (DGOS)-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Direction Générale de l'Organisation des Soins (DGOS)-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Université de Montréal [Montréal], Faculté de Médecine et de Pharmacie - Université de Poitiers, Faculté des Sciences du sport - Université de Poitiers, Université de Montréal, LESCA, and LESCA - Université du Québec à Montréal
Subjects: medicine.medical_specialty, Diastole, Blood Pressure, Physical Therapy, Sports Therapy and Rehabilitation, 030204 cardiovascular system & hematology, Prehypertension, Weighted mean difference, 03 medical and health sciences, Sex Factors, 0302 clinical medicine, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Weight loss, Weight Loss, medicine, Humans, Aerobic exercise, Orthopedics and Sports Medicine, pre-hypertension, 030212 general & internal medicine, 10. No inequality, Exercise, training, business.industry, Age Factors, Blood Pressure Determination, Blood Pressure Monitoring, Ambulatory, [ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Diet, Exercise Therapy, hypotensive, Blood pressure, Meta-analysis, Ambulatory, Hypertension, Physical therapy, medicine.symptom, business
Abstract: International audience; The effectiveness of regular exercise in decreasing both systolic and diastolic blood pressure (BP) is well-established. Our purpose was to assess the impact of both subject and physical activity program characteristics on ambulatory BP through a meta-analysis of the existing literature. Three databases (PubMed, Embase, Web of Science) were searched using relevant terms and strategies. From 637 identified records, 37 studies met inclusion criteria: details about training intervention and participant characteristics, pre- and post-training ambulatory BP measurements, at home (HBPM) or during 24-h (ABPM). The weighted mean difference was for 24-h systolic/diastolic ABPM (n = 847 participants): -4.06/-2.77 mmHg (95%CI: -5.19 to -2.93/-3.58 to -1.97; P < 0.001), for daytime (ABPM or HBPM, n = 983): -3.78/-2.73 mmHg (95%CI: -5.09 to -2.47/-3.57 to -1.89; P < 0.001) and nighttime ABPM periods (n = 796): -2.35/-1.70 mmHg (95%CI: -3.26 to -1.44/-2.45 to -0.95; P < 0.001). Characteristics significantly influencing BP improvement were: an initial office BP ≥130/85 mmHg and diet-induced weight-loss. We found no differences according to sex, age, or training characteristics (intensity, number of sessions, training duration). Antihypertensive effects of aerobic training assessed by ambulatory BP measurements appear significant and clinically relevant for both daytime and nighttime periods, in particular for participants with an office BP ≥130/85 mmHg.
Published: 2017
Full Text: View/download PDF

27. Efficacy and safety of DPP-4 inhibitors in patients with type 2 diabetes: Meta-analysis of placebo-controlled randomized clinical trials

Author: Marie-Christine Pérault-Pochat, P. Archambault, Jean-Luc Faillie, Michaela Beatrice Rehman, François Gueyffier, Catherine Cornu, J. Soustre, M. Buisson, Hélène Vaillant-Roussel, Denis Pouchain, Rémy Boussageon, Benoit Tudrej, Service de cardiologie [CHU de Poitiers], Centre hospitalier universitaire de Poitiers (CHU Poitiers), Université de Poitiers - Faculté de Médecine et de Pharmacie, Université de Poitiers, CIC 1407, Hospices Civils de Lyon (HCL), Université de Tours (UT), Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), CIC Clermont Ferrand, Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Gabriel Montpied [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand-Centre de Pharmacologie Clinique, CHU Clermont-Ferrand, Evaluation et modélisation des effets thérapeutiques, Département biostatistiques et modélisation pour la santé et l'environnement [LBBE], Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), CIC - Poitiers, Université de Poitiers-Centre hospitalier universitaire de Poitiers (CHU Poitiers)-Direction Générale de l'Organisation des Soins (DGOS)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU de Poitiers, Faculté de Médecine et de Pharmacie - Université de Poitiers, Hospices Civils de Lyon ( HCL ), Université de Tours, Université Clermont Auvergne ( UCA ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre de Pharmacologie Clinique-CHU Gabriel-Montpied, Laboratoire de Biométrie et Biologie Evolutive ( LBBE ), Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique ( Inria ) -Centre National de la Recherche Scientifique ( CNRS ), and Université de Poitiers-CHU de Poitiers-Direction Générale de l'Organisation des Soins (DGOS)-Institut National de la Santé et de la Recherche Médicale ( INSERM )
Subjects: medicine.medical_specialty, Endocrinology, Diabetes and Metabolism, Type 2 diabetes, Dipeptidyl peptidase-4 inhibitor, 030204 cardiovascular system & hematology, Placebo, law.invention, Micro- and macrovascular complications, 03 medical and health sciences, 0302 clinical medicine, Endocrinology, Randomized controlled trial, law, Internal medicine, DPP-4 inhibitors, Internal Medicine, medicine, Humans, 030212 general & internal medicine, Myocardial infarction, Mortality, Adverse effect, Randomized Controlled Trials as Topic, Dipeptidyl-Peptidase IV Inhibitors, business.industry, General Medicine, [ SDV.MHEP.EM ] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism, [SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism, medicine.disease, 3. Good health, Surgery, Meta-analysis, Diabetes Mellitus, Type 2, Sitagliptin, Acute pancreatitis, Randomized clinical trials, business, medicine.drug
Abstract: International audience; BACKGROUND:Guidelines for type 2 diabetes (T2D) recommend reducing HbA1c through lifestyle interventions and glucose-lowering drugs (metformin, then combination with dipeptidyl peptidase-4 inhibitors [DPP-4Is] among other glucose-lowering drugs). However, no double-blind randomized clinical trial (RCT) compared with placebo has so far demonstrated that DDP-4Is reduce micro- and macrovascular complications in T2D. Moreover, the safety of DPP-4Is (with increased heart failure and acute pancreatitis) remains controversial.METHODS:A systematic review of the literature (PubMed, Cochrane Library Central Register of Controlled Trials [CENTRAL] and https://clinicaltrials.gov), including all RCTs vs placebo published up to May 2015 and the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS), published June 2015, was performed. Primary endpoints were all-cause mortality and death from cardiovascular causes; secondary endpoints were macrovascular and microvascular events. Safety endpoints were acute pancreatitis, pancreatic cancer, serious adverse events and severe hypoglycaemia.RESULTS:A total of 36 double-blind RCTs were included, allowing analyses of 54,664 patients. There were no significant differences in all-cause mortality (RR=1.03, 95% confidence interval [CI]=0.95-1.12), cardiovascular mortality (RR=1.02, 95% CI=0.92-1.12), myocardial infarction (RR=0.98, 95% CI=0.89-1.08), strokes (RR=1.02, 95% CI=0.88-1.17), renal failure (RR=1.06, 95% CI=0.88-1.27), severe hypoglycaemia (RR=1.14, 95% CI=0.95-1.36) and pancreatic cancer (RR=0.54, 95% CI=0.28-1.04) with the use of DPP-4Is. However, DDP-4Is were associated with an increased risk of heart failure (RR=1.13, 95% CI=1.01-1.26) and of acute pancreatitis (RR=1.57, 95% CI=1.03-2.39).CONCLUSION:There is no significant evidence of short-term efficacy of DPP-4Is on either morbidity/mortality or macro-/microvascular complications in T2D. However, there are warning signs concerning heart failure and acute pancreatitis. This suggests a great need for additional relevant studies in future.
Published: 2017
Full Text: View/download PDF

28. Quality of qualitative studies centred on patients in family practice: a systematic review

Author: Eschalier, Benedicte, DESCAMPS, Stéphane, Pereira, Bruno, Vaillant-Roussel, Hélène, Girard, Guillaume, BOISGARD, Stéphane, Coudeyre, Emmanuel, Nazarian, Ara, Rehman, M., Tudrej, B.V., Soustre, J., Buisson, M., Archambault, P., Pouchain, D., Gueyffier, François, Faillie, J.-L., Perault-Pochat, C., Cornu, C., Boussageon, R., Cambon, Benoit, Vorilhon, Philippe, Michel, Laurence, Cadwallader, Jean-Sébastien, Aubin-Auger, Isabelle, Vaillant Roussel, Hélène, Département de Médecine Générale, Faculté de Médecine, Université Clermont Auvergne, Service d’Orthopédie Traumatologie [CHU Clermont-Ferrand], CHU Gabriel Montpied [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, Biostatistiques, Inferential, Institut de Chimie de Clermont-Ferrand (ICCF), SIGMA Clermont (SIGMA Clermont)-Institut de Chimie du CNRS (INC)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Centre National de la Recherche Scientifique (CNRS), médecine physique et de réadaptation, CHU Clermont-Ferrand, Center for Advanced Orthopaedic Studies, Harvard Medical School [Boston] (HMS), Service de cardiologie [CHU de Poitiers], Centre hospitalier universitaire de Poitiers (CHU Poitiers), Université de Poitiers - Faculté de Médecine et de Pharmacie, Université de Poitiers, Virologie et pathogenèse virale (VPV), Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, Institut des Sciences de la MER de Rimouski (ISMER), Université du Québec à Rimouski (UQAR), Université de Tours (UT), Evaluation et modélisation des effets thérapeutiques, Département biostatistiques et modélisation pour la santé et l'environnement [LBBE], Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), CIC 1407, Hospices Civils de Lyon (HCL), CIC CHU Lyon (inserm), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM), Département de Médecine Générale [Clermont-Ferrand], Faculté de Médecine - Clermont-Auvergne (FM - UCA), Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Université Sorbonne Paris Cité (USPC), Centre de recherche en épidémiologie et santé des populations (CESP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Recherche Clinique ville-hôpital, Méthodologies et Société (REMES), Université Paris Diderot - Paris 7 (UPD7), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), and Université de Tours
Subjects: Research design, medicine.medical_specialty, Biomedical Research, media_common.quotation_subject, Interviews as Topic, 03 medical and health sciences, 0302 clinical medicine, Medicine, Humans, Quality (business), Confidentiality, 030212 general & internal medicine, Research question, Qualitative Research, ComputingMilieux_MISCELLANEOUS, media_common, Data collection, Impact factor, business.industry, 030503 health policy & services, Focus Groups, Focus group, 3. Good health, Research Design, Family medicine, 0305 other medical science, business, Family Practice, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Qualitative research
Abstract: BACKGROUND Qualitative research is often used in the field of general medicine. Our objective was to evaluate the quality of published qualitative studies conducted using individual interviews or focus groups centred on patients monitored in general practice. METHODS We have undertaken a review of the literature in the PubMed and Embase databases of articles up to February 2014. The selection criteria were qualitative studies conducted using individual interviews or focus groups, centred on patients monitored in general practice. The articles chosen were analysed and evaluated using a score established from the Relevance, Appropriateness, Transparency and Soundness (RATS) grid. RESULTS The average score of the 52 studies chosen was 28 out of 42. The criteria least often present were the description of the patients who chose not to participate in the study, the justification of the end of data collection, the discussion of the influence of the researchers and the discussion of the confidentiality of the data. The criteria most frequently described were an explicit research question, justified and in relation to existing knowledge, the agreement of the ethical committee and the presence of quotations. The number of studies and the score increased from year-to-year. The score was independent of the impact factor of the journal. CONCLUSIONS Even though the qualitative research was published in reviews with a low impact factor, our results suggest that this research responded to the quality criteria of the RATS grid. The evaluation scored using RATS could be useful for authors or reviewers and for literature reviews.
Published: 2016
Full Text: View/download PDF

29. Adherence to Antihypertensive Treatment and the Blood Pressure–Lowering Effects of Renal Denervation in the Renal Denervation for Hypertension (DENERHTN) TrialClinical Perspective

Author: Azizi, Michel, Pereira, Helena, Hamdidouche, Idir, Gosse, Philippe, Monge, Matthieu, Bobrie, Guillaume, Delsart, Pascal, Mounier-Vehier, Claire, Courand, Pierre-Yves, Lantelme, Pierre, Denolle, Thierry, Dourmap-Collas, Caroline, Girerd, Xavier, Michel Halimi, Jean, Zannad, Faiez, Ormezzano, Olivier, Vaisse, Bernard, Herpin, Daniel, Ribstein, Jean, Chamontin, Bernard, Mourad, Jean-Jacques, Ferrari, Emile, Plouin, Pierre-Francois, Jullien, Vincent, Sapoval, Marc, Chatellier, Gilles, Investigators, DENERHTN, Université Paris Descartes - Paris 5 (UPD5), Service de médecine vasculaire et hypertension artérielle [CHU HEGP], Hôpital Européen Georges Pompidou [APHP] (HEGP), Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), CIC - HEGP (CIC 1418), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d’Épidémiologie et de Recherche Clinique [CHU HEGP], Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Hôpital Saint-André, Institut Mutualiste de Montsouris (IMM), Hôpital cardiologique, Université de Lille, Droit et Santé-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Hôpital de la Croix-Rousse [CHU - HCL], Hospices Civils de Lyon (HCL), Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé (CREATIS), Université Jean Monnet [Saint-Étienne] (UJM)-Hospices Civils de Lyon (HCL)-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de cardiologie et maladies vasculaires [CHU de Rennes], CHU Pontchaillou [Rennes], CHU Pitié-Salpêtrière [APHP], Hôpital Bretonneau, Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), CHU Grenoble, Hôpital de la Timone [CHU - APHM] (TIMONE), Service de cardiologie [CHU de Poitiers], Centre hospitalier universitaire de Poitiers (CHU Poitiers), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), CHU Toulouse [Toulouse], Hôpital avicenne, Université Paris 13 (UP13)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Avicenne, Centre Hospitalier Universitaire de Nice (CHU Nice), Epilepsies de l'Enfant et Plasticité Cérébrale (U1129), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Service de cardiologie et maladies vasculaires [Rennes] = Cardiac, Thoracic, and Vascular Surgery [Rennes], CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Avicenne [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), and Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université de Lyon-Université Claude Bernard Lyon 1 (UCBL)
Subjects: sympathetic nervous system, kidney, hypertension, medications, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, nervous system, ablation techniques
Abstract: International audience; BACKGROUND:The DENERHTN trial (Renal Denervation for Hypertension) confirmed the blood pressure-lowering efficacy of renal denervation added to a standardized stepped-care antihypertensive treatment for resistant hypertension at 6 months. We report the influence of adherence to antihypertensive treatment on blood pressure control.METHODS:One hundred six patients with hypertension resistant to 4 weeks of treatment with indapamide 1.5 mg/d, ramipril 10 mg/d (or irbesartan 300 mg/d), and amlodipine 10 mg/d were randomly assigned to renal denervation plus standardized stepped-care antihypertensive treatment, or the same antihypertensive treatment alone. For standardized stepped-care antihypertensive treatment, spironolactone 25 mg/d, bisoprolol 10 mg/d, prazosin 5 mg/d, and rilmenidine 1 mg/d were sequentially added at monthly visits if home blood pressure was ≥135/85 mm Hg after randomization. We assessed adherence to antihypertensive treatment at 6 months by drug screening in urine/plasma samples from 85 patients.RESULTS:The numbers of fully adherent (20/40 versus 21/45), partially nonadherent (13/40 versus 20/45), or completely nonadherent patients (7/40 versus 4/45) to antihypertensive treatment were not different in the renal denervation and the control groups, respectively (P=0.3605). The difference in the change in daytime ambulatory systolic blood pressure from baseline to 6 months between the 2 groups was -6.7 mm Hg (P=0.0461) in fully adherent and -7.8 mm Hg (P=0.0996) in nonadherent (partially nonadherent plus completely nonadherent) patients. The between-patient variability of daytime ambulatory systolic blood pressure was greater for nonadherent than for fully adherent patients.CONCLUSIONS:In the DENERHTN trial, the prevalence of nonadherence to antihypertensive drugs at 6 months was high (≈50%) but not different in the renal denervation and control groups. Regardless of adherence to treatment, renal denervation plus standardized stepped-care antihypertensive treatment resulted in a greater decrease in blood pressure than standardized stepped-care antihypertensive treatment alone.CLINICAL TRIAL REGISTRATION:URL: http://www.clinicaltrials.gov. Unique identifier: NCT01570777.
Published: 2016
Full Text: View/download PDF

30. SFE/SFHTA/AFCE primary aldosteronism consensus: Introduction and handbook

Author: Antoinette Pechère, Philippe Chaffanjon, Jean-Louis Kraimps, Fabrice Menegaux, Francis Joffre, Claire Douillard, Claire Mounier-Vehier, Jean Philippe Baguet, Pierre-François Plouin, Philippe Gosse, Daniel Herpin, Franck Zinzindohoue, Anne Hernigou, Xaxier Girerd, Yves Reznik, Stéphane Bardet, Maria-Christina Zennaro, Olivier Steichen, Jean-Yves Pagny, Pierre Durieux, Laurence Amar, Xavier Jeunemaitre, Olivier Chabre, Pascal Houillier, Hervé Lefebvre, Antoine Tabarin, Juerg Nussberger, Bernard Chamontin, Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Groupe Hospitalier Mutualiste [Grenoble] (GHM), Centre Régional de Lutte contre le Cancer François Baclesse [Caen] (UNICANCER/CRLC), UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU), Laboratoire d'Anatomie des Alpes Françaises (LADAF), CHU Grenoble, CHU Toulouse [Toulouse], Université Grenoble Alpes - UFR Médecine (UGA UFRM), Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Hôpital Saint-André, Service de cardiologie [CHU de Poitiers], Centre hospitalier universitaire de Poitiers (CHU Poitiers), Laboratoire de Robotique Interactive (LRI), Département Intelligence Ambiante et Systèmes Interactifs (DIASI), Laboratoire d'Intégration des Systèmes et des Technologies (LIST), Direction de Recherche Technologique (CEA) (DRT (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Direction de Recherche Technologique (CEA) (DRT (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Laboratoire d'Intégration des Systèmes et des Technologies (LIST), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay, Service de chirurgie générale et endocrinienne [CHU de Poitiers], Différenciation et communication neuronale et neuroendocrine (DC2N), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Rouen, Normandie Université (NU), Service de Chirurgie Générale, Viscérale et Endocrinienne [CHU Pitié-Sapêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Hôpital cardiologique, Université de Lille, Droit et Santé-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre Hospitalier Universitaire Vaudois [Lausanne] (CHUV), Hôpital Universitaire de Genève, Service Endocrinologie - Diabétologie [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), CHU Bordeaux [Bordeaux], Paris-Centre de Recherche Cardiovasculaire (PARCC (UMR_S 970/ U970)), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP), Centre Hospitalier Universitaire [Grenoble] (CHU), Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Laboratoire d'Intégration des Systèmes et des Technologies (LIST (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Laboratoire d'Intégration des Systèmes et des Technologies (LIST (CEA)), Hôpital Universitaire de Genève = University Hospitals of Geneva (HUG), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Paris-Centre de Recherche Cardiovasculaire (PARCC - UMR-S U970), Université Paris Descartes - Paris 5 (UPD5)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de médecine nucléaire, Centre Régional de Lutte contre le Cancer François Baclesse (CRLC François Baclesse ), Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Université Grenoble Alpes (UGA), Biomedical informatics and public health department, APHP, Unité des maladies rénales et métaboliques [Hôpital Européen Georges-Pompidou - APHP], Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Direction de Recherche Technologique (CEA) (DRT (CEA)), Département d'Endocrinologie, Diabète et Maladies Métaboliques [CHU Rouen], Normandie Université (NU)-Normandie Université (NU), Service de chirurgie générale d'endocrinologie [CHU Pitié–Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Pitié-Salpêtrière [APHP], Service d'Immunopathologie [Hôpital Saint-Louis, Paris], Université Paris Diderot - Paris 7 (UPD7)-CHU Saint Louis [APHP], Service d'Endocrinologie (BORDEAUX - Endocrino), Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Service d'endocrinologie, and CHU Grenoble-Hôpital Michallon
Subjects: Endocrinology, Diabetes and Metabolism, medicine.medical_treatment, Adrenal Gland Neoplasms, 030204 cardiovascular system & hematology, Spironolactone, Adrenal incidentaloma, chemistry.chemical_compound, 0302 clinical medicine, Endocrinology, Primary aldosteronism, Renin, Medicine, Aldosterone, ComputingMilieux_MISCELLANEOUS, Mineralocorticoid Receptor Antagonists, Adrenalectomy, General Medicine, [SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism, Calcium Channel Blockers, Hyperaldosteronism, Hypokalemia, 3. Good health, Eplerenone, Resistant hypertension, Hypertension, France, medicine.symptom, medicine.drug, Severe hypertension, Adult, medicine.medical_specialty, Consensus, 030209 endocrinology & metabolism, Hypokaliémie, 03 medical and health sciences, Internal medicine, Hyperaldostéronisme, [SDV.MHEP.PHY]Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO], Humans, Hypertension sévère, Hypertension résistante, business.industry, medicine.disease, Endocrine surgery, chemistry, Incidentalome surrénalien, business
Abstract: International audience; The French Endocrinology Society (SFE) French Hypertension Society (SFHTA) and Francophone Endocrine Surgery Association (AFCE) have drawn up recommendations for the management of primary aldosteronism (PA), based on an analysis of the literature by 27 experts in 7 work-groups. PA is suspected in case of hypertension associated with one of the following characteristics: severity, resistance, associated hypokalemia, disproportionate target organ lesions, or adrenal incidentaloma with hypertension or hypokalemia. Diagnosis is founded on aldosterone/renin ratio (ARR) measured under standardized conditions. Diagnostic thresholds are expressed according to the measurement units employed. Diagnosis is established for suprathreshold ARR associated with aldosterone concentrations > 550 pmol/L (200 pg/mL) on 2 measurements, and rejected for aldosterone concentration < 240 pmol/L (90 pg/mL) and/or subthreshold ARR. The diagnostic threshold applied is different if certain medication cannot be interrupted. In intermediate situations, dynamic testing is performed. Genetic forms of PA are screened for in young subjects and/or in case of familial history. The patient should be informed of the results expected from medical and surgical treatment of PA before exploration for lateralization is proposed. Lateralization is explored by adrenal vein sampling (AVS), except in patients under 35 years of age with unilateral adenoma on imaging. If PA proves to be lateralized, unilateral adrenalectomy may be performed, with adaptation of medical treatment pre- and postoperatively. If PA is non-lateralized or the patient refuses surgery, spironolactone is administered as first-line treatment, replaced by amiloride, eplerenone or calcium-channel blockers if insufficiently effective or poorly tolerated.; La SFE, la SFHTA et l’AFCE ont élaboré des recommandations sur la prise en charge de l’hyperaldostéronisme primaire (HAP), à partir d’une analyse de la littérature par 27 experts formant 7 groupes de travail. Un HAP est recherché devant une hypertension artérielle (HTA) présentant une des caractéristiques suivantes : sévère ; résistante ; associée à une hypokaliémie ; associée à un retentissement disproportionné sur les organes cibles, et devant un incidentalome surrénalien avec HTA ou hypokaliémie. Le diagnostic repose sur le rapport aldostérone/rénine (RAR) mesuré en conditions standardisées. L’expression du seuil diagnostique (SD) dépend des unités de mesure. Lorsque le RAR est > SD et l’aldostérone > 550 pmol/L (> 200 pg/mL) à 2 reprises, le diagnostic est affirmé, si aldostérone < 240 pmol/L (< 90 pg/mL) ou RAR < SD il est rejeté. Un SD différent est utilisé si certains médicaments ne peuvent être arrêtés. Dans les situations intermédiaires, un test dynamique est réalisé. Une forme génétique d’HAP est recherchée chez le sujet jeune et/ou en présence d’histoire familiale. Une information sur les résultats des traitements médicaux et chirurgicaux de l’HAP doit être donnée au patient avant de proposer la recherche d’une latéralisation. Celle-ci repose sur le cathétérisme des veines surrénaliennes (CVS), sauf patients < 35 ans avec image d’adénome unilatéral. Si l’HAP est latéralisé, une surrénalectomie unilatérale peut être proposée, elle est encadrée d’adaptations du traitement médical. Si l’HAP n’est pas latéralisé ou si le patient refuse la chirurgie la spironolactone est utilisée en première intention, amiloride, éplérenone, et inhibiteurs calciques sont utilisés si elle est insuffisement efficace ou mal tolérée.
Published: 2016
Full Text: View/download PDF

31. SFE/SFHTA/AFCE consensus on primary aldosteronism, part 7: Medical treatment of primary aldosteronism

Author: Daniel Herpin, Hervé Lefebvre, Antoinette Pechère-Bertschi, Hôpital Universitaire de Genève, Service de cardiologie [CHU de Poitiers], Centre hospitalier universitaire de Poitiers (CHU Poitiers), Différenciation et communication neuronale et neuroendocrine (DC2N), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Rouen, and Normandie Université (NU)
Subjects: Male, Endocrinology, Diabetes and Metabolism, 030204 cardiovascular system & hematology, Pharmacology, Spironolactone, Amiloride, chemistry.chemical_compound, 0302 clinical medicine, Endocrinology, Primary aldosteronism, Mineralocorticoid receptor, Éplérenone, Medicine, 030212 general & internal medicine, Cardiovascular morbidity, Mineralocorticoid Receptor Antagonists, General Medicine, [SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism, Hyperaldosteronism, Hypokalemia, 3. Good health, Eplerenone, Treatment Outcome, Hypertension, Female, France, medicine.symptom, medicine.drug, Calcic inhibitor, medicine.medical_specialty, Urology, [SDV.BC]Life Sciences [q-bio]/Cellular Biology, Morbidité cardiovasculaire, 03 medical and health sciences, [SDV.MHEP.PHY]Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO], Humans, Thiazide, Diurétique thiazidique, business.industry, Thiazide diuretic, Inhibiteur calcique, Hyperaldostéronisme primaire, medicine.disease, chemistry, business
Abstract: International audience; Spironolactone, which is a potent mineralocorticoid receptor antagonist, represents the first line medical treatment of primary aldosteronism (PA). As spironolactone is also an antagonist of the androgen and progesterone receptor, it may present side effects, especially in male patients. In case of intolerance to spironolactone, amiloride may be used to control hypokaliemia and we suggest that eplerenone, which is a more selective but less powerful antagonist of the mineralocorticoid receptor, be used in case of intolerance to spironolactone and insufficient control of hypertension by amiloride. Specific calcic inhibitors and thiazide diuretics may be used as second or third line therapy. Medical treatment of bilateral forms of PA seem to be as efficient as surgical treatment of lateralized PA for the control of hypertension and the prevention of cardiovascular and renal morbidities. This allows to propose medical treatment of PA to patients with lateralized forms of PA who refuse surgery or to patients with PA who do not want to be explored by adrenal venous sampling to determine whether they have a bilateral or lateralized form.; La spironolactone, antagoniste du récepteur minéralocorticoïde, est le médicament à proposer en première intention dans le traitement médical de l’hyperaldostéronisme primaire (HAP). Comme la spironolactone est également antagoniste du récepteur des androgènes et de la progestérone, elle a des effets indésirables en particulier chez l’homme. En cas d’intolérance à la spironolactone, l’amiloride permet un bon contrôle de l’hypokaliémie et nous suggérons que l’éplérénone, antagoniste plus sélectif du récepteur minéralocorticoïde, soit utilisée lorsqu’il existe une intolérance à la spironolactone et/ou une efficacité antihypertensive insuffisante de l’amiloride. En deuxième ou troisième ligne nous suggérons d’utiliser certains inhibiteurs calciques et ou thiazidique. Le traitement médical de l’HAP semble avoir une efficacité comparable au traitement chirurgical des formes latéralisées d’HAP, sur le plan des résultats tensionnels et du retentissement cardiovasculaire et rénal. De ce fait, le traitement médical de l’HAP peut être proposé aux patients porteurs d’un HAP latéralisé qui refuseraient la chirurgie ou aux patients porteurs d’un HAP qui refuseraient la réalisation d’un cathétérisme veineux surrénalien nécessaire pour déterminer si leur HAP est latéralisé ou non.
Published: 2016
Full Text: View/download PDF

32. Ambulatory blood pressure reduction following high-intensity interval exercise performed in water or dryland condition

Author: Vincent Gremeaux, Christopher Lemasson, Julie Lalongé, Philippe Sosner, D. Hayami, Laurent Bosquet, Martin Juneau, Mauricio Garzon, Olivier Dupuy, Mathieu Gayda, Mariel Gonzales, Anil Nigam, Laboratoire 'Mobilité, Vieillissement, Exercice' (MOVE) ( MOVE ), Université de Poitiers, Centre médico-sportif Mon Stade [Paris], Service de cardiologie [CHU de Poitiers], CHU de Poitiers, Centre EPIC [Institut de Cardiologie de Montréal], Université de Montréal [Montréal]-Montreal Heart Institute - Institut de Cardiologie de Montréal, Montreal Heart Institute - Institut de Cardiologie de Montréal, Department of Medicine, Montreal, Université de Montréal, université de montréal kinésiologie, Plateforme d’Investigation Technologique [Centre d’Investigation Clinique 1432 module Plurithématique - Dijon] ( PIT ), Cognition, Action, et Plasticité Sensorimotrice [Dijon - U1093] ( CAPS ), Université de Bourgogne ( UB ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université de Bourgogne ( UB ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre d'Investigation Clinique 1432 (Dijon) - Module Plurithématique : Périnatalité Cancérologie Handicap et Ophtalmologie ( CIC-P803 ), Université de Bourgogne ( UB ) -Direction Générale de l'Organisation des Soins (DGOS)-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Direction Générale de l'Organisation des Soins (DGOS)-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Université de Bourgogne ( UB ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Pôle Rééducation - Réadaptation (Médecine Physique et Réadaptation) (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon ), Laboratoire 'Mobilité, Vieillissement, Exercice' (MOVE) (MOVE), Centre hospitalier universitaire de Poitiers (CHU Poitiers), Université de Montréal (UdeM)-Montreal Heart Institute - Institut de Cardiologie de Montréal, Plateforme d’Investigation Technologique [Centre d’Investigation Clinique 1432 module Plurithématique - Dijon] (PIT), Cognition, Action, et Plasticité Sensorimotrice [Dijon - U1093] (CAPS), Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre d'Investigation Clinique 1432 (Dijon) - Module Plurithématique : Périnatalité Cancérologie Handicap et Ophtalmologie (CIC-P803), Université de Bourgogne (UB)-Direction Générale de l'Organisation des Soins (DGOS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Direction Générale de l'Organisation des Soins (DGOS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon)
Subjects: Male, Hemodynamics, Blood Pressure, 030204 cardiovascular system & hematology, High-Intensity Interval Training, Random Allocation, 0302 clinical medicine, prevention, Immersion, guidelines, physical-activity, Pulse wave velocity, high-intensity interval exercise, mechanisms, High intensity, Blood Pressure Monitoring, Ambulatory, Middle Aged, [ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, arterial stiffness, pulse-wave velocity, Hypertension, Practice Guidelines as Topic, Cardiology, Female, Ambulatory blood pressure monitoring, Cardiology and Cardiovascular Medicine, High-intensity interval training, management, hypertensive patients, medicine.medical_specialty, Ambulatory blood pressure, Diastole, men, 03 medical and health sciences, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Internal medicine, water exercise, Internal Medicine, medicine, Humans, Exercise, Aged, business.industry, Water, 030229 sport sciences, medicine.disease, postexercise hypotension, cardiac rehabilitation, Blood pressure, Physical therapy, Arterial stiffness, business
Abstract: International audience; We aimed to compare blood pressure (BP) responses following moderate-intensity continuous exercise (MICE), high intensity interval exercise (HIIE) in dry land or HIM in immersed condition, using 24-hour ambulatory BP monitoring. Forty-two individuals (65 +/- 7 years, 52% men) with a baseline BP >= 130/85 mm Hg (systolic/diastolic blood pressures [SBP/DBP]) were randomly assigned to perform one of the three following exercises on a stationary cycle: MICE (24 minutes at 50% peak power output) or HIIE in dry land (two sets of 10 minutes with phases of 15 seconds 100% peak power output interspersed by 15 seconds of passive recovery) or HIIE in up-to-the-chest immersed condition. While MICE modified none of the 24-hour average hemodynamic variables, dryland HIIE induced a 24-hour BP decrease (SBP: -3.6 +/- 5.7/DBP: -2.8 +/- 3.0 mm Hg, P < .05) and, to a much greater extent, immersed HIIE (SBP: -6.8 +/- 9.5/DBP: -3.0 +/- 4.5 mm Hg, P < .05). The one condition that modified 24-hour pulse-wave velocity was immersed HIIE (-0.21 +/- 0.30 m/s, P < .05).
Published: 2016
Full Text: View/download PDF

33. The Impact of Clinical and Genetic Findings on The Management of Young Brugada Syndrome Patients

Author: Andorin, Antoine, Behr, Elijah R., Denjoy, Isabelle, Crotti, Lia, Dagradi, Federica, Jesel, Laurence, Sacher, Frederic, Petit, Bertrand, Mabo, Philippe, Maltret, Alice, Wong, Leonie C. H., Degand, Bruno, Bertaux, Geraldine, Maury, Philippe, Dulac, Yves, Delasalle, Béatrice, Gourraud, Jean-Baptiste, Babuty, Dominique, Blom, Nico A., Schwartz, Peter J., Wilde, Arthur A., Probst, Vincent, CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de cardiologie, Université Paris Diderot - Paris 7 (UPD7)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Strasbourg, IHU-LIRYC, Université Bordeaux Segalen - Bordeaux 2-CHU Bordeaux [Bordeaux], Service de cardiologie et maladies vasculaires [Rennes] = Cardiac, Thoracic, and Vascular Surgery [Rennes], CHU Pontchaillou [Rennes], Laboratoire Traitement du Signal et de l'Image (LTSI), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de cardiologie pédiatrique [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de cardiologie [CHU de Poitiers], Centre hospitalier universitaire de Poitiers (CHU Poitiers), Service de Cardiologie [CHU de Dijon], Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), CHU Toulouse [Toulouse], Service pédiatrie-cardiologie, CHU Toulouse [Toulouse]-Hôpital des Enfants, unité de recherche de l'institut du thorax UMR1087 UMR6291 (ITX), Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Cardiopathies et mort subite [ERL 3147], Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), CHU Pitié-Salpêtrière [APHP], Université Paris Diderot - Paris 7 (UPD7)-AP-HP - Hôpital Bichat - Claude Bernard [Paris]-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), CHU Bordeaux [Bordeaux]-Université Bordeaux Segalen - Bordeaux 2, Service de cardiologie et maladies vasculaires, Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Necker - Enfants Malades [AP-HP], Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes (UN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Centre de référence pour les maladies cardiaques héréditaires, Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Pitié-Salpêtrière [APHP], Assistance publique - Hôpitaux de Paris (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris]-Université Paris Diderot - Paris 7 ( UPD7 ), Laboratoire d'étude des textures et application aux matériaux ( LETAM ), Université Paul Verlaine - Metz ( UPVM ) -Centre National de la Recherche Scientifique ( CNRS ), Université de Rennes 1 ( UR1 ), Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Laboratoire Traitement du Signal et de l'Image ( LTSI ), Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Département de Cardiologie, Université de Poitiers, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon ), unité de recherche de l'institut du thorax UMR1087 UMR6291 ( ITX ), Centre National de la Recherche Scientifique ( CNRS ) -Université de Nantes ( UN ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), CHU de Tours, Cardiopathies et mort subite, Université de Nantes ( UN ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Service Cardiologie pédiatrique [CHU Toulouse], Pôle Enfants [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Unité de recherche de l'institut du thorax (ITX-lab), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), and Université de Nantes (UN)-Université de Nantes (UN)
Subjects: Death sudden, [ SDV ] Life Sciences [q-bio], [SDV]Life Sciences [q-bio], Genetics, Brugada syndrome, cardiovascular diseases, Pediatrics, Arrhythmia
Abstract: International audience; Background - Brugada syndrome (BrS) is an arrhythmogenic disease associated with sudden cardiac death (SCD) that seldom manifests or is recognized in childhood. Objectives - The objectives of this study were to describe the clinical presentation of pediatric BrS to identify prognostic factors for risk stratification and to propose a data-based approach management. Methods - We studied 106 patients younger than 19 years at diagnosis of BrS enrolled from 16 European hospitals. Results - At diagnosis, BrS was spontaneous (n = 36, 34%) or drug-induced (n = 70, 66%). The mean age was 11.1 ± 5.7 years, and most patients were asymptomatic (family screening, (n = 67, 63%; incidental, n = 13, 12%), while 15 (14%) experienced syncope, 6(6%) aborted SCD or symptomatic ventricular tachycardia, and 5 (5%) other symptoms. During follow-up (median 54 months), 10 (9%) patients had life-threatening arrhythmias (LTA), including 3 (3%) deaths. Six (6%) experienced syncope and 4 (4%) supraventricular tachycardia. Fever triggered 27% of LTA events. An implantable cardioverter-defibrillator was implanted in 22 (21%), with major adverse events in 41%. Of the 11 (10%) patients treated with hydroquinidine, 8 remained asymptomatic. Genetic testing was performed in 75 (71%) patients, and SCN5A rare variants were identified in 58 (55%); 15 of 32 tested probands (47%) were genotype positive. Nine of 10 patients with LTA underwent genetic testing, and all were genotype positive, whereas the 17 SCN5A-negative patients remained asymptomatic. Spontaneous Brugada type 1 electrocardiographic (ECG) pattern (P = .005) and symptoms at diagnosis (P = .001) were predictors of LTA. Time to the first LTA event was shorter in patients with both symptoms at diagnosis and spontaneous Brugada type 1 ECG pattern (P = .006). Conclusion - Spontaneous Brugada type 1 ECG pattern and symptoms at diagnosis are predictors of LTA events in the young affected by BrS. The management of BrS should become age-specific, and prevention of SCD may involve genetic testing and aggressive use of antipyretics and quinidine, with risk-specific consideration for the implantable cardioverter-defibrillator.
Published: 2016
Full Text: View/download PDF

34. Niveau d’activité physique et contrôle ambulatoire de l’hypertension artérielle. Résultats de l’étude pilote « Acti-HTA »

Author: Sosner, Philippe, Ott, Julien, Steichen, O., Bally, Stéphane, Krummel, Thierry, Brucker, M., Lequeux, Benoît, Dourmap, Caroline, Llaty, P., LE COZ, Sylvie, Baguet, S., Miranne, A., Labrunée, M., Grémeaux, Vincent, Lopez-Sublet, M., Laboratoire 'Mobilité, Vieillissement, Exercice' (MOVE) ( MOVE ), Université de Poitiers, Service de néphrologie [Centre hospitalier de Haguenau], Centre hospitalier de Haguenau, Service de Médecine Interne [CHU Tenon], Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Tenon [APHP], Service de néphrologie - dialyse [Centre hospitalier Métropole Savoie - Chambéry], Centre Hospitalier Métropole Savoie [Chambéry], Service de néphrologie et hémodialyse [CHU de Strasbourg], CHU Strasbourg, Service de néphrologie [Centre hospitalier de Valence], Centre hospitalier de Valence, Service de cardiologie [CHU de Poitiers], CHU de Poitiers, Service de cardiologie et maladies vasculaires [CHU de Rennes], CHU Pontchaillou [Rennes], Service de néphrologie - dialyse [Centre hospitalier de Saint-Nazaire], Centre hospitalier de Saint-Nazaire, groupe hospitalier Mutualiste, Faculté de Médecine et de Pharmacie - Université de Poitiers, Service de médecine physique et réadaptation [Hôpital Rangueil - Toulouse], Hôpital de Rangueil, Cognition, Action, et Plasticité Sensorimotrice [Dijon - U1093] ( CAPS ), Université de Bourgogne ( UB ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Service de médecine interne [Avicenne], Hôpital Avicenne, Laboratoire 'Mobilité, Vieillissement, Exercice' (MOVE) (MOVE), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre hospitalier universitaire de Poitiers (CHU Poitiers), Service de cardiologie et maladies vasculaires [Rennes] = Cardiac, Thoracic, and Vascular Surgery [Rennes], Groupe Hospitalier Mutualiste [Grenoble] (GHM), Université de Poitiers - Faculté de Médecine et de Pharmacie, CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse], Cognition, Action, et Plasticité Sensorimotrice [Dijon - U1093] (CAPS), Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Avicenne [AP-HP], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)
Subjects: Activité physique, Caloric expenditure, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, High blood pressure, Physical activity, Hypertension, Home blood pressure measurement, Dépense énergétique, [ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Hypertension artérielle, Automesure tensionnelle
Abstract: Retour sur les 34èmes Journées de l’Hypertension Artérielle; International audience; While physical activity (PA) is recommended for high blood pressure management, the level of PA practice of hypertensive patients remains unclear. We aimed to assess the association between the level of both PA and blood pressure of individuals consulting in 9 hypertension specialist centres. Eighty-five hypertensive patients were included (59 ± 14 years, 61% men, 12% smokers, 29% with diabetes). Following their consultation, they performed home blood pressure measurement (HBPM) over 7 days (2 in the morning+2 in the evening), they wrote in a dedicated form their daily activities to estimate the additional caloric expenditure using Acti-MET device (built from International physical Activity Questionnaire [IPAQ]). Thus, patients completed a self-administered questionnaire "score of Dijon" (distinguishing active subjects with a score>20/30, from sedentary 20/30, des sédentaires < 10/30). Les hypertendus contrôlés en AMT (< 135/85 mm Hg) (55 % des sujets), en comparaison aux non contrôlés, étaient plus âgés, avaient une tendance non significative à une dépense calorique déclarée plus élevée (4959 ± 5045 kcal/semaine vs 4048 ± 4199 kcal/semaine, p = 0,3755) et leur score de Dijon (19,44 ± 5,81 vs 18,00 ± 4,32, p = 0,2094) montrait une proportion de sujets « actifs » plus importante (48,9 % vs 34,2 %, p = 0,1773). En conclusion, nos résultats ont objectivé une « tendance » à une AP déclarée plus importante pour les sujets dont l’HTA est contrôlée. Ceci nous encourage à poursuivre par une étude qui inclurait davantage de sujets et dont l’AP serait évaluée par le port pendant 7 jours d’un capteur de type accéléromètre (méthode objective).
Published: 2015
Full Text: View/download PDF

35. The ‘Ten Commandments’ of 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases

Author: Jean-Baptiste Ricco, Victor Aboyans, Service de Chirurgie Thoracique et Vasculaire - Médecine vasculaire [CHU Limoges], CHU Limoges, Neuroépidémiologie Tropicale (NET), CHU Limoges-Institut d'Epidémiologie Neurologique et de Neurologie Tropicale-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST), Université de Limoges (UNILIM)-Université de Limoges (UNILIM), Service de cardiologie [CHU de Poitiers], and Centre hospitalier universitaire de Poitiers (CHU Poitiers)
Subjects: medicine.medical_specialty, business.industry, Ten Commandments, MEDLINE, 030204 cardiovascular system & hematology, Peripheral Arterial Diseases, 3. Good health, 03 medical and health sciences, 0302 clinical medicine, 030220 oncology & carcinogenesis, medicine, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Cardiology and Cardiovascular Medicine, Intensive care medicine, business, ComputingMilieux_MISCELLANEOUS
Abstract: International audience
Published: 2018
Full Text: View/download PDF

36. Physical activity level and home blood pressure measurement: Pilot study 'Acti-HTA'

Author: S. Bally, M. Lopez-Sublet, Olivier Steichen, Vincent Gremeaux, Philippe Sosner, P. Llaty, M. Brucker, S. Le Coz, Benoit Lequeux, A. Miranne, C. Dourmap, Club des jeunes hypertensiologues, Thierry Krummel, J. Ott, S. Baguet, M. Labrunee, université de Bourgogne, CAPS, Laboratoire 'Mobilité, Vieillissement, Exercice' (MOVE) (MOVE), Université de Poitiers, Service de néphrologie [Centre hospitalier de Haguenau], Centre hospitalier de Haguenau, Service de Médecine Interne = Hôpital de jour de médecine [CHU Tenon], CHU Tenon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service de néphrologie - dialyse [Centre hospitalier Métropole Savoie - Chambéry], Centre Hospitalier Métropole Savoie [Chambéry], Service de néphrologie et hémodialyse [CHU de Strasbourg], CHU Strasbourg, Service de néphrologie [Centre hospitalier de Valence], Centre hospitalier de Valence, Service de cardiologie [CHU de Poitiers], Centre hospitalier universitaire de Poitiers (CHU Poitiers), Service de cardiologie et maladies vasculaires [Rennes] = Cardiac, Thoracic, and Vascular Surgery [Rennes], CHU Pontchaillou [Rennes], Service de néphrologie - dialyse [Centre hospitalier de Saint-Nazaire], Centre hospitalier de Saint-Nazaire, Groupe Hospitalier Mutualiste [Grenoble] (GHM), Université de Poitiers - Faculté de Médecine et de Pharmacie, Service Médecine physique et de réadaptation [CHU Toulouse], Pôle Neurosciences [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Pôle Santé publique et médecine publique [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Cognition, Action, et Plasticité Sensorimotrice [Dijon - U1093] (CAPS), Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de médecine interne [Avicenne], Hôpital Avicenne [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Laboratoire 'Mobilité, Vieillissement, Exercice' (MOVE) ( MOVE ), Service de Médecine Interne [CHU Tenon], Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Tenon [APHP], CHU de Poitiers, Service de cardiologie et maladies vasculaires [CHU de Rennes], groupe hospitalier Mutualiste, Faculté de Médecine et de Pharmacie - Université de Poitiers, Service de médecine physique et réadaptation [Hôpital Rangueil - Toulouse], Hôpital de Rangueil, Cognition, Action, et Plasticité Sensorimotrice [Dijon - U1093] ( CAPS ), Université de Bourgogne ( UB ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Hôpital Avicenne, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), and CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse]
Subjects: medicine.medical_specialty, Evening, Physical activity, Dépense énergétique, Hypertension artérielle, Caloric expenditure, High blood pressure, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Diabetes mellitus, Medicine, Motor activity, Morning, Automesure tensionnelle, Gynecology, Blood pressure management, business.industry, Home blood pressure measurement, Objective method, [ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, medicine.disease, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Activité physique, Blood pressure, Hypertension, Physical therapy, Cardiology and Cardiovascular Medicine, business
Abstract: While physical activity (PA) is recommended for high blood pressure management, the level of PA practice of hypertensive patients remains unclear. We aimed to assess the association between the level of both PA and blood pressure of individuals consulting in 9 hypertension specialist centres. Eighty-five hypertensive patients were included (59 ± 14 years, 61% men, 12% smokers, 29% with diabetes). Following their consultation, they performed home blood pressure measurement (HBPM) over 7 days (2 in the morning+2 in the evening), they wrote in a dedicated form their daily activities to estimate the additional caloric expenditure using Acti-MET device (built from International physical Activity Questionnaire [IPAQ]). Thus, patients completed a self-administered questionnaire "score of Dijon" (distinguishing active subjects with a score>20/30, from sedentary, Alors que la pratique régulière d’une activité physique (AP) est recommandée en cas d’hypertension artérielle (HTA), le niveau d’AP des sujets hypertendus reste mal connu. Notre objectif était d’étudier l’association entre le niveau d’AP et le caractère contrôlé ou non de l’HTA de sujets vus en consultation dans 9 centres spécialisés en HTA. Quatre-vingt-cinq sujets hypertendus ont été inclus (59 ± 14 ans, 61 % d’hommes, 12 % fumeurs, 29 % diabétiques). Au décours de leur consultation, une automesure tensionnelle (AMT) sur 7 jours (2 mesures le matin + 2 le soir) était réalisée, ainsi qu’un compte rendu de leurs activités quotidiennes permettant d’estimer la dépense calorique additionnelle à l’aide d’une réglette Acti-MET extrapolée du questionnaire international d’activités physiques (IPAQ). Les sujets complétaient ensuite un auto-questionnaire « score de Dijon » sur 30 points (distinguant les sujets actifs, score > 20/30, des sédentaires < 10/30). Les hypertendus contrôlés en AMT (< 135/85 mm Hg) (55 % des sujets), en comparaison aux non contrôlés, étaient plus âgés, avaient une tendance non significative à une dépense calorique déclarée plus élevée (4959 ± 5045 kcal/semaine vs 4048 ± 4199 kcal/semaine, p = 0,3755) et leur score de Dijon (19,44 ± 5,81 vs 18,00 ± 4,32, p = 0,2094) montrait une proportion de sujets « actifs » plus importante (48,9 % vs 34,2 %, p = 0,1773). En conclusion, nos résultats ont objectivé une « tendance » à une AP déclarée plus importante pour les sujets dont l’HTA est contrôlée. Ceci nous encourage à poursuivre par une étude qui inclurait davantage de sujets et dont l’AP serait évaluée par le port pendant 7 jours d’un capteur de type accéléromètre (méthode objective).
Published: 2015
Full Text: View/download PDF

37. Myotonic dystrophy type 1 mimics and exacerbates Brugada phenotype induced by Nav1.5 sodium channel loss-of-function mutation

Author: Solena Le Scouarnec, Aurélien Chatelier, Thomas Pambrun, Jean-Jacques Schott, Aurélie Mercier, Sylvie Patri, Bruno Degand, Mohamed Chahine, Patrick Bois, Service de cardiologie [CHU de Poitiers], Centre hospitalier universitaire de Poitiers (CHU Poitiers), Signalisation et Transports Ioniques Membranaires (STIM), Université de Tours-Université de Poitiers-Centre National de la Recherche Scientifique (CNRS), unité de recherche de l'institut du thorax UMR1087 UMR6291 (ITX), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Centre de recherche Université Laval Robert Giffard (CRULRG), Université Laval [Québec] (ULaval), Université de Poitiers-Université de Tours (UT)-Centre National de la Recherche Scientifique (CNRS), Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), and Université de Nantes (UN)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
Subjects: musculoskeletal diseases, Proband, congenital, hereditary, and neonatal diseases and abnormalities, medicine.medical_specialty, Patch-Clamp Techniques, Adolescent, Genotype, [SDV]Life Sciences [q-bio], DNA Mutational Analysis, Mutation, Missense, Nav1.5, Sudden death, Myotonic dystrophy, NAV1.5 Voltage-Gated Sodium Channel, Electrocardiography, Physiology (medical), Internal medicine, Cardiac conduction, medicine, Humans, Myotonic Dystrophy, Genetic Predisposition to Disease, cardiovascular diseases, Muscular dystrophy, Cells, Cultured, Brugada syndrome, Brugada Syndrome, biology, business.industry, medicine.disease, 3. Good health, Pedigree, Ajmaline, Endocrinology, Phenotype, cardiovascular system, biology.protein, Female, Cardiology and Cardiovascular Medicine, business, medicine.drug
Abstract: International audience; BACKGROUND: Myotonic dystrophy type 1 (DM1), a muscular dystrophy due to CTG-expansion in the DMPK gene, can cause cardiac conduction disorders and sudden death. These cardiac manifestations are similar to those observed in loss-of-function SCN5A mutations, which are also responsible for Brugada syndrome (BrS). OBJECTIVE: To investigate DM1 effects on the clinical expression of a loss-of-function SCN5A mutation causing BrS. METHODS: We performed complete clinical evaluation, including ajmaline test, in one family combining DM1 and BrS. We screened the known BrS susceptibility genes. We characterized an SCN5A mutation using whole-cell patch-clamp experiments associated to cell surface biotinylation. RESULTS: The proband, a 15-year old female, was a survivor of out-of-hospital cardiac arrest with ventricular fibrillation. She combined a DMPK CTG-expansion from the father's side and an SCN5A mutation (S910L) from the mother's side. S910L is a trafficking defective mutant inducing a dominant negative effect when transfected with wild-type Nav1.5. This loss-of-function SCN5A mutation caused a Brugada phenotype during the mother's ajmaline test. Surprisingly in the father, a DM1 patient without SCN5A mutation, ajmaline also unmasked a Brugada phenotype. Furthermore, association of both genetic abnormalities in the proband exacerbated the response to ajmaline with a massive conduction defect. CONCLUSIONS: Our study is the first to describe the deleterious effect of DM1 on the clinical expression of a loss-of-function SCN5A mutation and to show a provoked BrS phenotype in a DM1 patient. The modification of the electrocardiographic pattern by ajmaline supports the hypothesis of a link between DM1 and Nav1.5 loss-of-function.
Published: 2013
Full Text: View/download PDF

38. Prognosis of Adults With Isolated Left Ventricular Non-Compaction: Results of a Prospective Multicentric Study.

Author: Gerard H, Iline N, Martel H, Nguyen K, Richard P, Donal E, Eicher JC, Huttin O, Selton-Suty C, Raud-Raynier P, Jondeau G, Mansencal N, Sawka C, Ader F, Pruny JF, Casalta AC, Michel N, Donghi V, Faivre L, Giorgi R, Charron P, and Habib G
Abstract: Background: Whether left ventricular non-compaction (LVNC) bears a different prognosis than dilated cardiomyopathy (DCM) is still a matter of debate., Methods: From a multicenter French prospective registry, we compared the outcomes of 98 patients with LVNC and 65 with DCM. The primary endpoint combined cardiovascular death, heart transplantation, and hospitalization for cardiovascular events. The two groups presented similar outcomes but different left ventricular ejection fractions (LVEF) (43.3% in LVNC vs. 35.95% in DCM, p = 0.001). For this reason, a subgroup analysis was performed comparing only patients with LVEF ≤ 45%, including 56 with LVNC and 49 with DCM., Results: Among patients with LVEF ≤ 45%, at 5-year follow-up, the primary endpoint occurred in 33 (58.9%) among 56 patients with LVNC and 18 (36.7%) among 49 patients with DCM ( p = 0.02). Hospitalization for heart failure (18 [32.14%] vs. 5 [10.20%], p = 0.035) and heart transplantation were more frequent in the LVNC than in the DCM group. The incidences of rhythmic complications (24 [42.85%] vs. 12 [24.48%], p = 0.17), embolic events, and cardiovascular death were similar between LVNC and DCM cases. Among the 42 patients with LVNC and LVEF > 45%, the primary endpoints occurred in only 4 (9.52%) patients, including 2 hospitalizations for heart failure and 3 rhythmic complications, but no embolic events., Conclusion: In this prospective cohort, patients with LVNC who have left ventricular dysfunction present a poorer prognosis than DCM patients. Heart failure events were especially more frequent, but embolic events were not. Patients with LVNC and preserved ejection fraction present very few events in 5 years., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Gerard, Iline, Martel, Nguyen, Richard, Donal, Eicher, Huttin, Selton-Suty, Raud-Raynier, Jondeau, Mansencal, Sawka, Ader, Pruny, Casalta, Michel, Donghi, Faivre, Giorgi, Charron and Habib.)
Published: 2022
Full Text: View/download PDF

39. Phenotype/Genotype Relationship in Left Ventricular Noncompaction: Ion Channel Gene Mutations Are Associated With Preserved Left Ventricular Systolic Function and Biventricular Noncompaction: Phenotype/Genotype of Noncompaction.

Author: Cambon-Viala M, Gerard H, Nguyen K, Richard P, Ader F, Pruny JF, Donal E, Eicher JC, Huttin O, Selton-Suty C, Raud-Raynier P, Jondeau G, Mansencal N, Sawka C, Casalta AC, Michel N, Donghi V, Martel H, Faivre L, Charron P, and Habib G
Subjects: Genotype, Humans, Ion Channels, Mutation, Phenotype, Ventricular Function, Left, Heart Failure, Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels genetics, Isolated Noncompaction of the Ventricular Myocardium diagnostic imaging, Isolated Noncompaction of the Ventricular Myocardium genetics, Muscle Proteins genetics, Potassium Channels genetics, Ryanodine Receptor Calcium Release Channel genetics
Abstract: Background: Few data exist concerning genotype-phenotype relationships in left ventricular noncompaction (LVNC)., Methods and Results: From a multicenter French Registry, we report the genetic and clinical spectrum of 95 patients with LVNC, and their genotype-phenotype relationship. Among the 95 LVNC, 45 had at least 1 mutation, including 14 cases of mutation in ion channel genes. In a complementary analysis including 16 additional patients with ion channel gene mutations, for a total of 30 patients with ion channel gene mutation, we found that those patients had higher median LV ejection fraction (60% vs 40%; P < .001) and more biventricular noncompaction (53.1% vs 18.5%; P < .001) than the 81 other patients with LVNC. Among them, both the 19 patients with an HCN4 mutation and the 11 patients with an RYR2 mutation presented with a higher LV ejection fraction and more frequent biventricular noncompaction than the 81 patients with LVNC but with no mutation in the ion channel gene, but only patients with HCN4 mutation presented with a lower heart rate., Conclusions: Ion channel gene mutations should be searched systematically in patients with LVNC associated with either bradycardia or biventricular noncompaction, particularly when LV systolic function is preserved. Identifying causative mutations is of utmost importance for genetic counselling of at-risk relatives of patients affected by LVNC., (Copyright © 2021 Elsevier Inc. All rights reserved.)
Published: 2021
Full Text: View/download PDF

40. Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial.

Author: Silvain J, Lattuca B, Beygui F, Rangé G, Motovska Z, Dillinger JG, Boueri Z, Brunel P, Lhermusier T, Pouillot C, Larrieu-Ardilouze E, Boccara F, Labeque JN, Guedeney P, El Kasty M, Laredo M, Dumaine R, Ducrocq G, Collet JP, Cayla G, Blanchart K, Kala P, Vicaut E, and Montalescot G
Subjects: Clopidogrel adverse effects, Clopidogrel therapeutic use, Elective Surgical Procedures, Female, Humans, Male, Middle Aged, Treatment Outcome, Percutaneous Coronary Intervention adverse effects, Platelet Aggregation Inhibitors adverse effects, Platelet Aggregation Inhibitors therapeutic use, Purinergic P2Y Receptor Antagonists therapeutic use, Ticagrelor therapeutic use
Abstract: Background: Percutaneous coronary intervention (PCI)-related myonecrosis is frequent and can affect the long-term prognosis of patients. To our knowledge, ticagrelor has not been evaluated in elective PCI and could reduce periprocedural ischaemic complications compared with clopidogrel, the currently recommended treatment. The aim of the ALPHEUS study was to examine if ticagrelor was superior to clopidogrel in reducing periprocedural myocardial necrosis in stable coronary patients undergoing high-risk elective PCI., Methods: The ALPHEUS study, a phase 3b, randomised, open-label trial, was done at 49 hospitals in France and Czech Republic. Patients with stable coronary artery disease were eligible for the study if they had an indication for PCI and at least one high-risk characteristic. Eligible patients were randomly assigned (1:1) to either ticagrelor (180 mg loading dose, 90 mg twice daily thereafter for 30 days) or clopidogrel (300-600 mg loading dose, 75 mg daily thereafter for 30 days) by use of an interactive web response system, and stratified by centre. The primary outcome was a composite of PCI-related type 4 (a or b) myocardial infarction or major myocardial injury and the primary safety outcome was major bleeding, both of which were evaluated within 48 h of PCI (or at hospital discharge if earlier). The primary analysis was based on all events that occurred in the intention-to-treat population. The trial was registered with ClinicalTrials.gov, NCT02617290., Findings: Between Jan 9, 2017, and May 28, 2020, 1910 patients were randomly assigned at 49 sites, 956 to the ticagrelor group and 954 to the clopidogrel group. 15 patients were excluded from the ticagrelor group and 12 from the clopidogrel group. At 48 h, the primary outcome was observed in 334 (35%) of 941 patients in the ticagrelor group and 341 (36%) of 942 patients in the clopidogrel group (odds ratio [OR] 0·97, 95% CI 0·80-1·17; p=0·75). The primary safety outcome did not differ between the two groups, but minor bleeding events were more frequently observed with ticagrelor than clopidogrel at 30 days (105 [11%] of 941 patients in the ticagrelor group vs 71 [8%] of 942 patients in the clopidogrel group; OR 1·54, 95% CI 1·12-2·11; p=0·0070)., Interpretation: Ticagrelor was not superior to clopidogrel in reducing periprocedural myocardial necrosis after elective PCI and did not cause an increase in major bleeding, but did increase the rate of minor bleeding at 30 days. These results support the use of clopidogrel as the standard of care for elective PCI., Funding: ACTION Study Group and AstraZeneca., (Copyright © 2020 Elsevier Ltd. All rights reserved.)
Published: 2020
Full Text: View/download PDF

41. Effectiveness of Deep Sedation for Patients With Intractable Electrical Storm Refractory to Antiarrhythmic Drugs.

Author: Martins RP, Urien JM, Barbarot N, Rieul G, Sellal JM, Borella L, Clementy N, Bisson A, Guenancia C, Sagnard A, Schumacher S, Gandjbakhch E, Duchateau J, Tixier R, Goepp A, Hamon D, Lellouche N, Champ-Rigot L, Milliez P, Marijon E, Varlet E, Garcia R, Degand B, Bouju P, Mabo P, Leclercq C, Behar N, Pavin D, de Chillou C, Sacher F, and Galand V
Subjects: Aged, Humans, Anti-Arrhythmia Agents therapeutic use, Deep Sedation methods, Tachycardia, Ventricular drug therapy
Published: 2020
Full Text: View/download PDF

42. Ambulatory blood pressure reduction following 2 weeks of high-intensity interval training on an immersed ergocycle.

Author: Sosner P, Gayda M, Dupuy O, Garzon M, Gremeaux V, Lalongé J, Hayami D, Juneau M, Nigam A, and Bosquet L
Subjects: Adult, Aged, Aged, 80 and over, Bicycling, Blood Pressure Monitoring, Ambulatory, Female, Humans, Hypertension diagnosis, Hypertension physiopathology, Immersion, Male, Middle Aged, Quebec, Time Factors, Treatment Outcome, Blood Pressure, High-Intensity Interval Training methods, Hypertension therapy
Abstract: Background: Hypertension guidelines recommend moderate-intensity continuous training (MICT) for the primary or secondary prevention of hypertension. However, alternative modalities, such as high-intensity interval training (HIIT) on dry land or in water, have been studied less widely., Aim: To assess chronic blood pressure (BP) response to a 2-week training programme involving six sessions of either MICT or HIIT performed on dry land or HIIT performed in an immersed condition, in participants with baseline office systolic/diastolic BP (SBP/DBP)≥130/85mmHg., Methods: We randomly assigned 42 individuals (mean age 65±7 years; 52% men) with baseline office SBP/DBP≥130/85mmHg to perform six 24-minute sessions on an ergocycle (three times a week for 2 weeks) of either MICT on dry land, HIIT on dry land or HIIT in a swimming pool, and assessed BP responses using 24-hour ambulatory BP monitoring., Results: While 2-week MICT and HIIT on dry land modified none of the 24-hour average haemodynamic variables significantly, immersed HIIT induced a significant decrease in 24-hour BP (SBP -5.1±7.3 [P=0.02]; DBP -2.9±4.1mmHg [P=0.02]) and daytime BP (SBP -6.2±8.3 [P=0.015]; DBP -3.4±4.0mmHg [P=0.008]), and slightly improved 24-hour and daytime pulse wave velocity (PWV) (24-hour PWV -0.17±0.23m/s [P=0.015]; daytime PWV -0.18±0.24m/s [P=0.02])., Conclusion: HIIT on an immersed stationary ergocycle is an innovative method that should be considered as an efficient non-pharmacological treatment of hypertension. As such, it should now be implemented in a larger cohort to study its long-term effects on the cardiovascular system., (Copyright © 2019 Elsevier Masson SAS. All rights reserved.)
Published: 2019
Full Text: View/download PDF

43. No prognostic role of a GWAS-derived genetic risk score in renal outcomes for patients from French cohorts with type 1 and type 2 diabetes.

Author: Barbieux P, György B, Gand E, Saulnier PJ, Ducrocq G, Halimi JM, Feigerlova E, Hulin-Delmotte C, Llaty P, Montaigne D, Rigalleau V, Roussel R, Sosner P, Zaoui P, Ragot S, Marre M, Tregouët DA, and Hadjadj S
Subjects: Aged, Female, Genome-Wide Association Study, Humans, Male, Middle Aged, Prognosis, Diabetes Mellitus, Type 1 genetics, Diabetes Mellitus, Type 2 genetics, Diabetic Nephropathies genetics, Genetic Predisposition to Disease, Polymorphism, Single Nucleotide
Published: 2019
Full Text: View/download PDF

44. Targeted panel sequencing in adult patients with left ventricular non-compaction reveals a large genetic heterogeneity.

Author: Richard P, Ader F, Roux M, Donal E, Eicher JC, Aoutil N, Huttin O, Selton-Suty C, Coisne D, Jondeau G, Damy T, Mansencal N, Casalta AC, Michel N, Haentjens J, Faivre L, Lavoute C, Nguyen K, Tregouët DA, Habib G, and Charron P
Subjects: Adult, Alleles, Biomarkers, Computational Biology methods, Echocardiography, Female, Genetic Variation, Genotype, Humans, Male, Middle Aged, Mutation, Pedigree, Phenotype, Ventricular Dysfunction, Left diagnosis, Ventricular Dysfunction, Left genetics, Cardiomyopathies diagnosis, Cardiomyopathies genetics, Genetic Association Studies methods, Genetic Heterogeneity, Genetic Predisposition to Disease, High-Throughput Nucleotide Sequencing
Abstract: Left ventricular non-compaction (LVNC) is a cardiomyopathy that may be of genetic origin; however, few data are available about the yield of mutation, the spectrum of genes and allelic variations. The aim of this study was to better characterize the genetic spectrum of isolated LVNC in a prospective cohort of 95 unrelated adult patients through the molecular investigation of 107 genes involved in cardiomyopathies and arrhythmias. Fifty-two pathogenic or probably pathogenic variants were identified in 40 patients (42%) including 31 patients (32.5%) with single variant and 9 patients with complex genotypes (9.5%). Mutated patients tended to have younger age at diagnosis than patients with no identified mutation. The most prevalent genes were TTN, then HCN4, MYH7, and RYR2. The distribution includes 13 genes previously reported in LVNC and 10 additional candidate genes. Our results show that LVNC is basically a genetic disease and support genetic counseling and cardiac screening in relatives. There is a large genetic heterogeneity, with predominant TTN null mutations and frequent complex genotypes. The gene spectrum is close to the one observed in dilated cardiomyopathy but with specific genes such as HCN4. We also identified new candidate genes that could be involved in this sub-phenotype of cardiomyopathy., (© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
Published: 2019
Full Text: View/download PDF

45. Contractibility sensor signal evolution predicts cardiovascular events in patients with cardiac resynchronization therapy.

Author: Garcia R, Guenancia C, Le Gal F, Rehman M, Tao V, Christiaens L, Ingrand P, and Degand B
Subjects: Aged, Equipment Design, Female, Heart Failure diagnosis, Heart Failure mortality, Heart Failure physiopathology, Humans, Male, Middle Aged, Predictive Value of Tests, Retrospective Studies, Risk Factors, Signal Processing, Computer-Assisted, Tachycardia, Ventricular diagnosis, Tachycardia, Ventricular mortality, Tachycardia, Ventricular physiopathology, Time Factors, Treatment Outcome, Cardiac Resynchronization Therapy adverse effects, Cardiac Resynchronization Therapy mortality, Cardiac Resynchronization Therapy Devices, Death, Sudden, Cardiac prevention & control, Heart Failure therapy, Myocardial Contraction, Tachycardia, Ventricular therapy, Telemetry instrumentation, Transducers, Ventricular Function, Left
Abstract: Background: While a multicentre trial has demonstrated that the SonR™ contractibility sensor is as effective as echocardiography-guided optimization at improving response to cardiac resynchronization therapy, an association between SonR™ values and clinical endpoints has not been established., Aims: The primary objective was to assess the predictive value of SonR™ signal evolution regarding cardiovascular events in patients implanted with a cardiac resynchronization therapy device. The secondary objective was to evaluate whether SonR™ signal evolution was associated with cardiovascular death., Methods: All patients with a SonR™ system implanted between 2012 and 2016 were included in this retrospective study. SonR™ signal evolution was calculated over the first 6 months after implantation: ([month 6 value-month 1 value]/month 1 value)*100. The primary endpoint (cardiovascular events) was a composite of cardiovascular death, hospitalization for acute heart failure or ventricular arrhythmia., Results: Seventy-four patients (median age 67 years; 81% men) were followed up over a median 20 (13; 29) months. Cumulative incidence function showed that SonR™ signal evolution was predictive of cardiovascular events (threshold<10.70%; P=0.023) and predictive of cardiovascular death (P=0.0018). After multivariable analysis, SonR™ signal evolution was independently associated with the onset of cardiovascular events (hazard ratio: 4.03, 95% confidence interval: 1.31-12.43; P=0.015), even after adjustment for left bundle branch block and chronic kidney disease., Conclusions: In this first study publishing data on SonR™ signals in a real-life setting, SonR™ signal evolution over the first 6 months after cardiac resynchronization implantation was an independent predictor of cardiovascular events at follow-up. This variable could be useful to identify patients at higher risk of further adverse events after cardiac resynchronization implantation., (Copyright © 2018 Elsevier Masson SAS. All rights reserved.)
Published: 2019
Full Text: View/download PDF

46. Prognostic value of plasma MR-proADM vs NT-proBNP for heart failure in people with type 2 diabetes: the SURDIAGENE prospective study.

Author: Fraty M, Velho G, Gand E, Fumeron F, Ragot S, Sosner P, Mohammedi K, Gellen B, Saulnier PJ, Halimi JM, Montaigne D, Ducrocq G, Rehman M, Marre M, Roussel R, and Hadjadj S
Subjects: Adrenomedullin blood, Aged, Biomarkers blood, Diabetes Mellitus, Type 2 blood, Female, Heart Failure blood, Humans, Male, Middle Aged, Neuropeptides blood, Prognosis, Prospective Studies, Diabetes Mellitus, Type 2 pathology, Heart Failure pathology, Natriuretic Peptide, Brain blood, Peptide Fragments blood
Abstract: Aims/hypothesis: N-terminal pro-B-type natriuretic peptide (NT-proBNP) is the gold standard prognostic biomarker for diagnosis and occurrence of heart failure. Here, we compared its prognostic value for the occurrence of congestive heart failure with that of plasma mid-region pro-adrenomedullin (MR-proADM), a surrogate for adrenomedullin, a vasoactive peptide with vasodilator and natriuretic properties, in people with type 2 diabetes., Methods: Plasma MR-proADM concentration was measured in baseline samples of a hospital-based cohort of consecutively recruited participants with type 2 diabetes. Our primary endpoint was heart failure requiring hospitalisation., Results: We included 1438 participants (age 65 ± 11 years; 604 women and 834 men). Hospitalisation for heart failure occurred during follow-up (median 64 months) in 206 participants; the incidence rate of heart failure was 2.5 (95% CI 2.2, 2.9) per 100 person-years. Plasma concentrations of MR-proADM and NT-proBNP were significantly associated with heart failure in a Cox multivariable analysis model when adjusted for age, diabetes duration, history of coronary heart disease, proteinuria and baseline eGFR ( adj HR [95%CI] 1.83 [1.51, 2.21] and 2.20 [1.86, 2.61], respectively, per 1 SD log 10 increment, both p < 0.001). MR-proADM contributed significant supplementary information to the prognosis of heart failure when we considered the clinical risk factors (integrated discrimination improvement [IDI, mean ± SEM] 0.021 ± 0.007, p = 0.001) (Table 3). Inclusion of NT-proBNP in the multivariable model including MR-proADM contributed significant complementary information on prediction of heart failure (IDI [mean ± SEM] 0.028 ± 0.008, p < 0.001). By contrast, MR-proADM did not contribute supplementary information on prediction of heart failure in a model including NT-proBNP (IDI [mean ± SEM] 0.003 ± 0.003, p = 0.27), with similar results for heart failure with reduced ejection fraction and preserved ejection fraction., Conclusions/interpretation: MR-proADM is a prognostic biomarker for heart failure in people with type 2 diabetes but gives no significant complementary information on prediction of heart failure compared with NT-proBNP.
Published: 2018
Full Text: View/download PDF

47. Circulating Concentrations of Redox Biomarkers Do Not Improve the Prediction of Adverse Cardiovascular Events in Patients With Type 2 Diabetes Mellitus.

Author: Cournot M, Burillo E, Saulnier PJ, Planesse C, Gand E, Rehman M, Ragot S, Rondeau P, Catan A, Gonthier MP, Feigerlova E, Meilhac O, and Hadjadj S
Subjects: Aged, Biomarkers blood, Cardiovascular Diseases diagnosis, Diabetes Mellitus, Type 2 diagnosis, Female, Hemolysis, Humans, Male, Middle Aged, Oxidation-Reduction, Predictive Value of Tests, Prognosis, Prospective Studies, Protein Carbonylation, Risk Assessment, Risk Factors, Serum Albumin, Human, Time Factors, Advanced Oxidation Protein Products blood, Cardiovascular Diseases etiology, Diabetes Mellitus, Type 2 blood, Diabetes Mellitus, Type 2 complications, Glycation End Products, Advanced blood, Oxidative Stress
Abstract: Background: Despite pathophysiological relevance and promising experimental data, the usefulness of biomarkers of oxidative stress for cardiac risk prediction is unclear. The aim of our study was to investigate the prognostic value of 6 biomarkers exploring different pathways of oxidative stress for predicting adverse cardiovascular outcomes in patients with type 2 diabetes mellitus beyond established risk factors., Methods and Results: The SURDIAGENE (Survie, Diabete de type 2 et Genetique) prospective cohort study consecutively recruited 1468 patients with type 2 diabetes mellitus. Assays were performed at baseline, and incident cases of major adverse cardiovascular events (MACE)-first occurrence of cardiovascular death, nonfatal myocardial infarction, or stroke-were recorded during a median of 64 months. Advanced oxidation protein products, oxidative hemolysis inhibition assay, ischemia-modified albumin, and total reductive capacity of plasma were not associated with the risk of MACE in univariate analyses. Fluorescent advanced glycation end products and carbonyls were associated with MACE (hazard ratio=1.38 per SD, 95% confidence interval 1.24-1.54, P <0.001 and hazard ratio=1.15 per SD, 95% confidence interval 1.04-1.27, P =0.006, respectively) in univariate analysis, but when added to a multivariate predictive model including traditional risk factors for MACE, these markers did not significantly improve c-statistics or integrated discrimination index of the model., Conclusions: These plasma concentrations of 6 markers, which cover a broad spectrum of oxidative processes, were not significantly associated with MACE occurrence and were not able to improve MACE risk discrimination and classification beyond classical risk factors in type 2 diabetes mellitus patients., (© 2018 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.)
Published: 2018
Full Text: View/download PDF

48. Electrical atrial vulnerability and renal complications in type 2 diabetes.

Author: Montaigne D, Coisne A, Sosner P, Lacroix D, and Hadjadj S
Subjects: Female, Humans, Male, Albuminuria complications, Atrial Fibrillation etiology, Blood Pressure physiology, Diabetes Mellitus, Type 2 complications, Hypertension complications
Published: 2016
Full Text: View/download PDF

49. [High blood pressure and physical exercise].

Author: Sosner P, Gremeaux V, Bosquet L, and Herpin D
Subjects: Diet, Guidelines as Topic, Humans, Risk Factors, Exercise, Hypertension physiopathology, Hypertension prevention & control, Life Style
Abstract: High blood pressure is a frequent pathology with many cardiovascular complications. As highlighted in guidelines, the therapeutic management of hypertension relies on non-pharmacological measures, which are diet and regular physical activity, but both patients and physicians are reluctant to physical activity prescription. To acquire the conviction that physical activity is beneficial, necessary and possible, we can take into account some fundamental and clinical studies, as well as the feedback of our clinical practice. Physical inactivity is a major risk factor for cardiovascular morbidity and mortality, and hypertension contributes to increase this risk. Conversely, regular practice of physical activity decreases very significantly the risk by up to 60%. The acute blood pressure changes during exercise and post-exercise hypotension differs according to the dynamic component (endurance or aerobic and/or strength exercises), but the repetition of the sessions leads to the chronic hypotensive benefit of physical activity. Moreover, physical activity prescription must take into account the assessment of global cardiovascular risk, the control of the hypertension, and the opportunities and desires of the patient in order to promote good adherence and beneficial lifestyle change., (Copyright © 2014 Elsevier Masson SAS. All rights reserved.)
Published: 2014
Full Text: View/download PDF

50. [Anti-arrhythmia efficacy of propafenone per os in the prevention of paroxysmal supraventricular arrhythmia resistant to class Ia agents].

Author: Boutaud P, Guillem JP, Maarek-Charbit M, Amiel A, Ciber M, Herpin D, and Demange J
Subjects: Administration, Oral, Aged, Disopyramide therapeutic use, Drug Evaluation, Drug Resistance, Female, Humans, Male, Middle Aged, Propafenone administration & dosage, Quinidine therapeutic use, Propafenone therapeutic use, Tachycardia, Paroxysmal prevention & control, Tachycardia, Supraventricular prevention & control
Abstract: The efficacy of orally administered propafenone in the prevention of paroxysmal supraventricular dysrhythmias (atrial fibrillation, atrial tachysystole, reciprocal tachycardia) resistant to Vaughan-Williams class Ia drugs was investigated in 10 patients. Propafenone controlled dysrhythmia very well in 4 out of the ten patients, and satisfactorily in another one at a dosage ranging from 450 to 900 mg/day in 3 or 4 divided doses; this result was documented using continuous 24 hr. Holter ECG monitoring. Among the 5 clinical failures, 1 patient had atrial fibrillation primarily at night, and another poorly tolerated this agent which led to interrupt therapy.
Published: 1989

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Database

Publisher

50 results on '"Service de cardiologie [CHU de Poitiers]"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources